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1  INTRODUCTION 
 
 
A high percentage of medicinal drugs used in western medicine are derived from natural 
products and therefore ethno-pharmacological remedies of exotic civilisations can be a rich 
source for the development of novel drugs [CRAGG et al., 2006]. Particularly the rainforests 
possess an incredible potential concerning medicinal genetic resources, some of which may 
yield drugs to treat numerous diseases [CSEKE et al., 2006]. The majority of drugs used in 
western medicine are derivatives of naturally occurring substances (metabolites of plant or 
microbial origin) [CRAGG et al., 2006]. 
 
A success story in natural product drug discovery is paclitaxel (Taxol ®) from the bark of the 
Pacific Yew, Taxus brevifolia Nutt. (Taxaceae). The antitumor activity of Taxol is based on 
its ability to stabilize microtubules in tumor cells, promoting mitotic arrest and cell death. 
Several Native American tribes have used Taxus species for the treatment of non-cancerous 
diseases [CRAGG and NEWMAN, 2005]. 
 
There are innumerable higher plants, which have not been explored phytochemically yet. But 
it is anticipated that many of them contain bioactive compounds for the development of drugs 
to combat cancer diseases. Thus, we concentrate on the medicine of the Maya, who developed 
an advanced pharmaceutical science because of their habitat, the world`s third richest in 
numbers of vascular plant species [BORCHARDT, 2004]. 
 
For the first time the anti-cancer activity of extracts of the ethnopharmocological Mayan 
healing plant, Pluchea odorata (Asteracea), was described by Gridling et al. The most active 
dichloromethane extract was specially investigated, whereby it showed distinct anti-
proliferative effects. Its pro-apoptotic properties were massive. Conclusively substantiated the 
dichloromethane extract of P. odorata may contain several pro-apoptotic principles. Hence, 
the effectiveness of the extract may be based on the synergism of these principles 
[GRIDLING et al., 2009]. 
 
The aim of recent investigations was separating these principles with strong anti-neoplastic 
activity derived from the aerial parts of P. odorata (L.) Cass., which are used by the Maya to 
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treat severe inflammatory conditions. Hence, bioassay-guided fractionation was carried out to 
enrich the active compounds. The plant material was subsequently extracted with different 
solvents: petroleum ether and dichloromethane. The dichloromethane extract by ASE showed 
the highest anti-proliferative activity on HL60 cell line. Thus, it was re-chromatographed by 
Vacuum Liquid Chromatography (methanol-water in different ratios), normal Column 
Chromatography (chloroform-methanol-water gradient) on silica gel KG60, and RP-18 Solid 
Phase Extraction (methanol-water). 
 
The obtained fractions were tested in human HL60 promyelocytic leukaemia cells regarding 
their anti-cancerogenic properties. Furthermore, the most potent isolated fractions were 
investigated on their apoptosis-inducing potential. Western blotting displayed data on the 
underlying mechanisms. The bioassay-guided fractionation indicated that the anti-
proliferative activity of P. odorata was due to a fraction containing highly apolar constituents. 
Qualitative investigations on other Pluchea species reported sesquiterpenes and flavonoids as 
major compounds [FATOPE et al., 2004; VERA et al., 2008]. Positive reactions with 
spraying reagent anisaldehyde sulphuric acid on TLC propose the prescence of sesquiterpenes 
in the active fractions. 
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2  LITERATURE SURVEY 
 
2.1  CANCER 
 
2.1.1  Cell cycle and cancer 
 
The mammalian cell cycle consists of four phases, G1, S phase, G2 and M phase, each of 
which should be completed successfully before the next begins. Through major cell cycle 
transitions the progression of eukaryotic cells is mediated. Thereby, the sequential assembly 
and activation of cyclin dependent kinases (CDK) is important [VIALLARD et al., 2001]. 
The aberrant regulation of the cell cycle can lead to carcinogenesis. Mutations in genes of the 
molecular components of the growth factor signaling pathway and in genes that code for 
regulation of the cell cycle can lead to growth signal autonomy, one of the six hallmarks of 
cancer. 
 
Cell cycle progression, as an ordered and tightly-regulated process, involves multiple 
checkpoints that assess extracellular growth signals, cell size and DNA integrity. For the 
induction of cell cycle progression cyclin dependent kinases (CDKs) and their cyclin partners 
are positive regulators and cyclin dependent kinase inhibitors (CKIs) are negative regulators. 
There are two types of CKIs, the INK4 family and the CIP/KIP family, of which, p21, directly 
inducible by p53, is an example. The abnormal expression or activation of positive regulators 
and suppression of negative regulators can be one origin of cancer [PARK and LEE, 2003]. 
 
2.1.2  What is Cancer? 
 
Cancer is broadly defined as group of diseases, in which cells in a part of the body begin to 
grow out of control. More than 100 cancer types have been classified. The tissues of origin 
consist of epithelial cells (carcinomas), mesoderm cells (sarcomas) or glandular tissue 
(adenocarcinomas), such as breast tissue. Cancers differ in characteristics, therefore treatment 
must be adapted [PECORINO, 2008]. 
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2.1.3  The six hallmarks of Cancer 
 
A goal of cancer research is to find opportunities to counteract mechanisms of malignant 
tumors and thereby reduce mortality rate with cancer as the underlying cause of death. 
Considering the numerous and complex properties of cancers, the six essential alterations in 
cell physiology that collectively dictate malignant growth, were experimentally discovered by 
Hanahan and Weinberg [2000]. These alterations are essential for carcinogenesis and thereby 
they are also potential targets for the design of new therapeutics [PECORINO, 2008]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1  Six essential alterations in cell physiology [HANAHAN and WEINBERG, 2000] 
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2.1.3.1  Acquired functional capabilities of cancer cells 
 
 Self-sufficiency in growth signals 
 Insensitivity to antigrowth signals 
 Evading apoptosis 
 Limitless potential for replication  
 Sustained angiogenesis 
 Tissue invasion and metastasis 
 
The defined hallmarks can be found in most types of human cancer. Cancer is characterized 
by unregulated cell growth and most carcinogens are agents that cause alterations to the DNA 
sequence or mutations, therefore cancer results from alterations in DNA [PECORINO, 2008]. 
 
2.1.3.1.1  Self-sufficiency in growth signals 
 
Cancer cells are able to proliferate by producing their own mitogenic growth signals, 
independent on normal growth factor signaling. Thereby, tumor cells are reducing their 
dependence on stimulation from their microenvironment, hence a critically important 
homeostatic mechanism for ensuring a proper behaviour of cell types is disrupted. In contrast 
the division of normal cells needs external signals from growth factors. Growth factor 
pathways that are affected by acquired mutations lead to unregulated growth. 
 
There are different molecular strategies for achieving growth signal autonomy, involving 
alteration of extracellular growth signals, of transcellular transducers of those signals, or of 
intracellular circuits that translate those signals into action [HANAHAN and WEINBERG, 
2000]. Many cancer cells acquire the ability to create a positive feedback signaling loop often 
termed autocrine stimulation, whereby they obviate dependence on GFs from other cells 
[FEDI et al., 1997]. 
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During tumor pathogenesis cell surface receptors, that transduce growth-stimulatory signals 
are deregulated. The overexpression of GF receptors, occuring in many cancers, may enable 
the cancer cell to become hyper-responsive to ambient levels of growth factors. 
 
Ligand-independent signaling, elicited by gross overexpression of GF receptors, can also be 
the result of structural alteration of receptors [HANAHAN and WEINBERG, 2000]. 
Moreover cancer cells are able to switch the types of expressed extracellular matrix receptors 
(integrins), favoring receptors which transmit pro-growth signals. These cell surface receptors 
link cells to the extracellular matrix (ECM), whereby the integrin receptors gain ability to 
transduce signals that provoke various cell behaviours, ranging from quiescence to motility, 
resistance to apoptosis and entrance into the cell cycle. The failure of binding can impair cell 
motility, induce apoptosis, or cause cell cycle arrest [GIANCOTTI and RUOSLAHTI, 1999]. 
 
In the majority of human tumors cell-to-cell growth signaling operates, because the several 
distinct cell types appear to communicate via heterotypic signaling. And tumor cells are able 
to co-opt their normal neighbours by inducing them to release abundant fluxes of growth-
stimulation signals [SKOBE and FUSENIG, 1998]. 
 
2.1.3.1.2  Insensitivity to antigrowth signals 
 
To maintain homeostasis cells respond to inhibitory signals, but cancer cells do not, because 
acquired mutations interfere with the inhibitory pathways [PECORINO, 2008]. There are 
multiple antiproliferative signals within normal tissues to maintain homeostasis; these are 
soluble growth inhibitors and immobilized inhibitors in the extracellular matrix. 
 
Antigrowth signals are able to block proliferation, whereby they operate with two distinct 
mechanisms. Cells may be forced out of the active proliferative cycle into the quiescent (G0) 
state, and when extracellular signals permit, cells may reemerge. Otherwise, cells may be 
induced to enter into post-mitotic states and therefore permanently relinquish their 
proliferative potential [HANAHAN and WEINBERG, 2000]. 
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To prosper incipient cancer cells have to evade these antiproliferative signals. Perhaps all 
proliferative signals are funneled through the retinoblastoma protein (pRb), that blocks 
proliferation, when in a hypophosphorylated state [WEINBERG, 1995]. Cancer cells have the 
opportunity to disrupt the pRb pathway, whereby E2Fs is liberated and thus allows cell 
proliferation. The pRb signaling circuit can be disrupted in a variety of ways. 
 
Cancer cells are also able to turn off expression of integrins or other cell adhesion molecules. 
Thereby antigrowth signals are blocked, but those that convey progrowth signals are 
favoured. Cell proliferation is not only depending on mere avoidance of cytostatic antigrowth 
signals, but i.e on constraining cell multiplication by instructing cells to enter irreversibly into 
post-mitotic states by using diverse mechanisms that are incompletely understood. It is 
apparent that tumor cells use various strategies to avoid terminal differentiation [HANAHAN 
and WEINBERG, 2000]. 
 
2.1.3.1.3  Evading apoptosis (programmed cell death) 
 
Cancer cells are able to evade apoptotic signals, but normal cells are removed by apoptosis. 
Expansion of cell number is determined by the rate of cell proliferation, but also by the rate of 
programmed cell death (apoptosis). One hallmark of most and perhaps all types of cancer may 
be the acquired resistance toward apoptosis. The apoptotic program may be present in all cell 
types throughout the body, whereby this program is triggered by various signals and it unfolds 
in a series of steps, until the shriveled cell corpse is engulfed by nearby cells and disappears. 
There are two classes of components of the apoptotic machinery, sensors and effectors. 
Sensors are monitoring the extracellular and intracellular environment and they regulate the 
second class of components, the effectors of apoptotic death. 
 
Cytochrome C, a potent catalyst of apoptosis, is released by mitochondria. Many of the 
signals, that elicit apoptosis, converge on mitochondria [GREEN and REED, 1998]. The 
various proteins of the Bcl-2 family, which have either proapoptotic or antiapoptotic function, 
are able to act through cytochrome C release. Cytochrome C released from mitochondria can 
activate intracellular proteases, termed caspase 8 and caspase 9, which are able to activate 
more effector caspases, that execute the death program through destruction of the genome 
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[HANAHAN and WEINBERG, 2000]. The investigations of apoptosis in cancer at the 
molecular level were opened up by the discovery of the upregulation of bcl-2 oncogen via 
chromosomal translocation in follicular lymphoma and it`s recognition as having 
antiapoptotic activity [VAUX et al., 1988]. Existing data indicate that the presence of 
overexpressed oncogenes can trigger the apoptotic program. 
 
2.1.3.1.4  Limitless Replicative Potential 
 
Cancer cells are able to maintain the length of their telomeres that results in unlimited 
replicative potential. Within normal cells the chromosomal ends, telomeres, are shortened 
during every round of DNA replication. That is an autonomous counting device to define a 
finite number of cell doublings [PECORINO, 2008]. 
 
Not only growth signal autonomy, insensitivity to antigrowth signals and resistance to 
apoptosis does ensure expansive tumor growth, but also failures in an intrinsic, cell-
autonomous program that otherwise limits the multiplication of perhaps all types of 
mammalian cells. When this program is disrupted a clone of cells expands to a size that 
constitutes a macroscopic, life-threatening tumor. 
 
Cells in culture have a finite replicative potential, after a certain number of doublings cells 
stop growing – a process termed senescence. The circumvention of senescence is possible by 
disabling their pRb and p53 tumor suppressor proteins. Thereby, cells are able to continue 
multiplying for additional generations, until they enter into the crisis state. This state is 
characterized by massive cell death, but also the occasional emergence of a variant cell that 
has acquired the ability of immortalization [WRIGHT et al., 1989]. 
 
The counting devices for cell generations are the ends of chromosomes. These telomeres are 
consisting of several thousand repeats of short 6 bp sequence element. During each cell cycle 
telomeric DNA loses approximately 100 bp, the replicative cell generations lose their ability 
to protect the ends of chromosomal DNA, that results in the death of the affected cells 
[COUNTER et al., 1992]. 
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In virtually all types of malignant cells telomerase maintenance is evident and clearly a key 
component of the capability for unlimited replication [SHAY and BACCHETTI, 1997]. There 
are two mechanisms to maintain telomeres. On the one hand, malignant cells doing so by 
upregulating expression of the telomerase enzyme. The enzyme adds hexanucleotide repeats 
onto the ends of telomeric DNA [BRYAN and CECH,1999]. On the other hand, cells activate 
a mechanism, termed ALT. Thereby the maintenance of telomeres is through recombination-
based interchromosomal exchanges of sequence information [BRYAN et al., 1995]. 
 
2.1.3.1.5  Sustained angiogenesis (formation of new blood vessels) 
 
Blood vessels are responsible for supplying normal cells with oxygen and nutrients. Cancer 
cells are able to induce angiogenesis, the growth of new blood vessels. That is necessary for 
survival and expansion of tumors. The imbalance between angiogenic inducers and inhibitors 
can activate the angiogenic switch [PECORINO, 2008]. 
 
During organogenesis growth is coordinated and once a tissue is formed, the process of 
angiogenesis is carefully regulated. The evidence is, that cells within aberrant proliferative 
lesions initially lack angiogenic ability, curtailing their capability for expansion. Incipient 
neoplasias have to develop angiogenic ability to progress a larger size [HANAHAN and 
FOLKMAN, 1996]. 
 
Angiogenesis is couraged or blocked by counterbalancing positive and negative signals. There 
are angiogenesis-initiating signals like vascular endothelial growth factor (VEGF) and acidic 
and basic fibroblast growth factors (FGF1/2). One angiogenesis inhibitor is thrombospondin-
1. Tumors seem to gain the ability to induce and sustain angiogenesis during development, via 
an „angiogenic switch“. Tumor angiogenesis offers an attractive therapeutic target 
[HANAHAN and WEINBERG, 2000]. 
 
2.1.3.1.6  Tissue Invasion and Metastasis 
 
During the development of most types of human cancer, pioneer cells are spawn that travel to 
distant sites, where they found new colonies. These metastases are the cause of most human 
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cancer deaths. Invasion and metastasis are very complex processes, but also allied processes 
and utilizing similar operational strategies. In cells possessing invasive or metastatic 
capabilities, several classes of proteins are altered. The affected proteins include cell-cell 
adhesion molecules (CAMs), such as E-cadherin, and integrins, which link cells to 
extracellular matrix substrates, whereby all of these „adherence“ interactions convey 
regulatory signals to the cell (APLIN et al., 1998]. E-cadherin acts as a suppressor of invasion 
and metastasis by epithelial cancers. 
 
Changes in expression of CAMs and integrin appear to play critical roles in the processes of 
invasion and metastasis. Also extracellular proteases are involved in invasive and metastatic 
capability, whereby protease genes are upregulated, protease inhibitor genes are 
downregulated, and inactive forms of proteases are converted into active enzymes. Clearly 
central to the acquisition of invasiveness and metastatic ability are the activation of 
extracellular proteases and the altered binding specificities of cadherins, CAMs, and integrins 
[HANAHAN and WEINBERG, 2000]. 
 
 
2.1.4  Cancer and Inflammation 
 
Many types of cancer are caused by inflammation and specific infectious agents, through 
several mechanisms, which are involved in the process of cancer initiation and promotion. 
Especially long-term exposure to infectious agents and chronic inflammation can lead to 
cancer, but these causes of human cancer can be prevented. 
 
There are various viruses and bacteria, acting as infectious agents involved in carcinogenesis. 
Some viral and bacterial infections are able to induce a chronic inflammatory response that 
contributes to carcinogenesis. Under normal conditions inflammation is a defense mechanism 
against infectious agents, which is highly regulated. But around a tumor the body creates an 
inflammatory microenvironment characterized by inflammatory cells, growth factors, and 
reactive oxygen/nitrogen species [PECORINO, 2008]. 
 
The linkage between inflammation and cancer is part of an paradigm of carcinogenesis, 
becauce smoldering, nonresolving inflammation sets the stage for mutagenesis, angiogenesis 
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and metastasis [BALKWILL and MANTOVANI, 2010]. The possible mechanisms of this 
linkage includes induction of genomic instability, alterations in epigenetic events and 
subsequent inappropriate gene expression, enhanced proliferation, resistance to apoptosis and 
tumor neovascularization [KUNDU and SURH, 2008]. 
 
Approximately 20 % of all malignancies are initiated or exacerbated by inflammation, 
whereby the aggravation of inflammation is effected by increased production of cytokines, 
proteolytic enzymes, lipid mediators and prostaglandins. Also the infiltration of macrophages 
is a common feature of inflammation and angiogenesis. Therefore inflammatory and 
angiogenic responses can be targets for development of anticancer therapeutic drugs [ONO, 
2008]. 
 
 
2.1.5  Apoptosis 
 
The highly regulated process of cell death controls cell numbers and gets rid of cells, that 
have extensive DNA damage, it therefore plays an important role in tumor suppression. The 
aberrant regulation of cell growth, differentiation and apoptosis can give rise to tumors. 
Apoptotic cells are characterized by shrinkage, membrane blebbing, chromatin condensation 
and precise fragmentation. And they are swept clean during phagocytosis by macrophages. 
This contrasts with the process of necrosis. Cells swell, membranes become leaky and cells 
spill out their contents into the surrounding tissue and cause inflammation [PECORINO, 
2008]. 
 
2.1.6  Cell death programs 
 
The cells of metazoans have developed complex self-destruction mechanisms, collectively 
called programmed cell death, which includes the invention of intrinsic and extrinsic trigger 
factors. In multicellular organisms homeostasis is maintained by the balance between cell 
proliferation and cell death. There are several morphologically discernible forms of cell death. 
 
The type I cell death is divided into caspase-dependent apoptosis and caspase-independent 
apoptosis. Caspase-dependent apoptosis is a process of cell suicide eliminating unwanted 
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cells. Apoptosis involves the action of catabolic enzymes (proteases like caspases, nucleases) 
and stepwise DNA degradation. The remaining material is phagosytosed by unaffected 
neighboring cells. 
 
In a caspase-independent fashion the apoptotic chromatin degradation can be achieved also by 
AIF (apoptosis inducing factor). The two mechanisms of apoptosis execution exist together 
and may cooperate. 
 
The type II cell death involves lysosomes for the cell death by autophagy, whereby parts of 
membranes of subcellular organelles such as Golgi assemble to autophagosomes. The 
difference to apoptosis is the remaining intact cytoskeleton. Type I and type II cell death can 
occur in mixed form within the same tissue or cell type and even within the same cell. 
Apoptosis is required for homeostasis, hence the dis-regulation of cell death programs, more 
specifically, an abnormal resistance to apoptosis induction causes inter alia cancer due to the 
persistence of mutated cells. 
 
When apoptotic execution pathways are blocked or as a result of a variety of stresses the 
necrotic (accidental) cell death can occur. Co-occuring are also self destruction programs, 
which stand in apparent contrast to necrosis. Apoptosis and other forms of active cell death 
are major factors in the evolution of multicellular organisms [HUETTENBRENNER et al., 
2002]. 
 
 
2.2  CURRENT STATE OF RESEARCH – GENUS PLUCHEA 
 
Gridling et al. undertook preceding investigations on Pluchea odorata (L.) Cass. (Santa 
Maria), a plant used by the Maya to treat inflammatory conditions. Novel therapeutic concepts 
were tested in the human promyeloic leukaemia cell line HL60. The concept of plant selection 
was their traditional use against severe inflammations, because there are various similar 
signalling pathways both in inflammatory conditions and in cancer. 
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The most effective extract of P. odorata was the dichloromethane extract, suggesting that the 
active principle(s) is (are) non-polar compound(s), which inhibited inflammatory responses 
and exhibit anti-cancer activity [GRIDLING, 2008]. To isolate these compounds the bioassay-
guided fractionation of the P. odarata CH2Cl2 extract was task of this diploma thesis and also 
current investigations. 
 
The genus Pluchea (Asteraceae), comprising 80 species, contains various compounds. The 
leaves of Pluchea carolinensis (Jacq.) G. Don, a branched shrub from the Caribbean and 
surrounding regions, contains terpenoids, such as alpha-amyrin. Derivatives of cuauthemone 7 
and 9 to 15, which are found in abundance in Pluchea, were found in aerial parts of Pluchea 
carolinensis [ROBINEAU, 1991]. 
 
Two sesquiterpenes, godotol A and godotol B, were isolated from Pluchea arabica. Previous 
investigations of Pluchea plants have shown the presence of eudesmane sesquiterpenes, 
monoterpenes, lignan glycosides, pentacyclic triterpenoids and flavanoids [FATOPE et al., 
2004]. Also Marwah describes the wound-healing plant Pluchea arabica, traditionally used to 
treat sores and boils, containing the phytoconstituents sesquiterpenes, flavonoids, chromones 
and eudesmanes [MARWAH et al., 2007]. Decoctions of Pluchea sagittalis are used in 
traditional medicine and antioxidant and anti-inflammatory effects by CH2Cl2 extracts have 
been reported [PÉREZ-GARCÍA et al., 1996,2005]. 
 
The root extract of the Indian medicinal plant Pluchea indica (L.) Less.(Asteraceae) contains 
β-sitosterol and stigmasterol [GOMES et al., 2007] and eudesmane-type sesquiterpenes, 
plucheols A, B and plucheoside E. And the pure compound R/J/3 was isolated from Pluchea 
indica (L.) Less., a plant which is known for its anti-inflammatory activities and the isolated 
Tiophen showed the most pronounced anti-proliferative activity [BISWAS et al., 2005]. 
 
From the whole plant of Pluchea arguta a eudesmane sesquiterpene was isolated and 
identified as 4-epiplucheinol [AHMAD and FIZZA, 1986]. Plucheinol and (3αH)-plucheinol 
are eudesmane-type sesquiterpenes isolated from Pluchea chingoyo [ZABEL et al., 1982].  
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The genus Pluchea contains various flavonoids, the commonly known compounds 
isorhamnetin was isolated from P. symphytifolia W. T. Gillis and for the first time eupalitin 
has been isolated from Pluchea genera [CORDOVA et al., 2006]. 
 
From the leaves of Pluchea odorata (L.) Cass. four derivatives of a dehydroeudesman-8-one 
were obtained [ARRIAGA-GINER et al., 1983]. Two eudesmane derivatives, plucheinol and 
its monoester derivative 3α(2´,3´-dihydroxy-2´-methyl-butyryl oxy)-4α,11-dihydroxy-6,7-
dehydroeudesman-8-one were isolated as minor constituents [ARRIAGA and BORGES-
DEL-CASTILLO, 1985]. Investigations of the roots of Pluchea odorata Cass. yields a 
carvotagetone derivative and the phthalic acid derivative, while the aerial parts contain 
besides the already known eudesmane derivative two further compounds of this type 
[BOHLMANN and ZDERO, 1975]. 
 
Whether the different P. odorata populations also exhibit different anti-cancer activity needs 
to be established and could elucidate which type(s) of the plant constituents may be 
responsible for the described anti-neoplastic effects. 
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3  MATERIAL AND METHODS 
 
3.1  PLANT 
 
Pluchea odorata (L.) Cass. (Santa Maria) 
 
  
Figure 2  Pluchea odorata  Figure 3  Pluchea odorata: florescence 
 
http://www.researchlearningcenter.org/bloom/species/Pluchea_odorata 
 
 
Kingdom:  Plantae 
Division:  Magnoliophyta 
Class:  Magnoliopsida 
Subclassis:  Asteridae 
Order:  Asterales 
Family:  Asteraceae 
Genus:  Pluchea 
Species:  Pluchea odorata 
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The family of Asteraceae is probably the largest family of flowering plants. It includes more 
than 25,000 species world-wide, growing everywhere. The family Asteraceae shows 
remarkable variation in growth form and morphology because they occur in so many different 
localities and habitats. 
 
Pluchea odorata (L.) Cass., by common name Saltmarsh Fleabane, Sweet-scent or in Central 
America known as Santa Maria, has pink to lavender coloured flowers. It is a woody shrub up 
to 3 metres high and with aromatic leaves. The distribution ranges from Northern America to 
the states of Southern America: Belize, Guatemala, Panama, Puerto Rico, Venezuela and 
Ecuador. It is used in traditional medicine as an antidote, astringent, diaphoretic and 
emmenagogue agent.  
 
It is used as a treatment against common cold, hypertension, neuralgia and pneumonia 
[JOHNSON, 1999]. In traditional medicine it is prepared like tea. Therefore three leaves of P. 
odorata are boiled in three cups of water for two minutes followed by 15 minutes of steeping. 
This beverage is used against asthma attacks, coughs and colds, but also as ablutions against 
swellings, tumors and inflammations [ARVIGO and BALICK, 1994]. 
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3.2  SAMPLE PREPARATION 
 
The fresh plant material of P. odorata from Guatemala has been stored deep-frozen at   -80°C. 
For further extraction procedures the aerial plant parts, leaves, caulis and florescence of P. 
odorata were lyophilized. 
 
3.3  EXTRACTION WITH DICHLOROMETHANE (CH2Cl2) 
 
First the freeze dried plant parts were milled (RETSCH ZM 100). Afterwards the obtained 
powder was extracted. To obtain the dichloromethane extract, 20 g milled plant was mixed 
with 200 ml (1:10) of petroleum ether (PE) and treated in an ultra sonic bath for 10 minutes to 
break the cell walls of the plant. Then it was placed to a reflux-water bath at 40°C (table 1). 
 
After 1 hour the solvent was filtered through a round filter (Schleicher & Schuell, 
Microscience, 595, Ref Nr 10311612 – diameter 150 nm). 
 
- The retained plant material (residue) was dried on a sheet of paper over night, before 
reuse for next extraction with dichloromethane. 
 
- The liquid phase (solvent), which contained the dissolved material, was evaporated by 
a rotavapor (Heidolph WB 2001) and a water bath at 40°C until complete dryness. 
 
The dried retained plant material was mixed with 200 ml (1:10) of CH2Cl2 and treated in an 
ultra sonic bath for 10 minutes. Then it was placed to a reflux-water bath at 50°C (table 1). 
 
After 1 hour the solvent was filtered through a round filter. The liquid phase (solvent) which 
contained the dissolved material was evaporated under vacuum by a rotavapor until complete 
dryness. 
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3.4  EXTRACTION WITH CHLOROFORM (CHCl3) 
 
To obtain the chloroform extract, 20 g milled plant material was mixed with 200 ml (1:10) of 
methanol (MeOH) and treated in an ultra sonic bath for 10 minutes to break the cell walls of 
the plant. Then it was placed to a reflux-water bath at 79°C (table 1). 
 
After 1 hour the solvent was filtered through a round filter. The supernatant liquid phase 
(solvent), which contained the dissolved material was evaporated under vacuum by a 
rotavapor until complete dryness. 
 
The retained MeOH extract was dissolved in 100 ml MeOH:H2O (9:1) and afterwards it was 
degreased with 100 ml petroleum ether. The mixture of immiscible liquids was put into a 
separating funnel, shaken and allowed to settle for three times. 
 
The obtained PE extract was evaporated and stored. The aqueous MeOH extract was mixed 
with 100 ml H2O (1:1). By using a separating funnel the partition with 200 ml CHCl3 was 
carried out. 
 
The aqueous extract was evaporated and stored. The chloroform extract was washed twice 
with 200 ml saline solution (NaCl 1%) and Na2SO4 (Natrium sulfuricum siccatum) was added 
to eliminate contained water out of the organic solvent. After filtering through a round filter 
the chloroform extract was evaporated. 
 
 
 
 
solvent °C of reflux water bath evaporator mbar 
petroleum ether 40 650 
dichloromethane 50 650 
methanol 79 300 
Table 1  Solvents and their temperature and pressure for evaporation 
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3.5  EXTRACTION OF P. ODORATA WITH CH2Cl2 BY ASE 200 - 
accelerated solvent extractor (DIONEX) 
 
 
 
Figure 4  ASE 200 
http://www.dionex.com/enus/webdocs/4198_ASE_200_V10.pdf 
 
 
The ASE 200 Accelerated Solvent Extractor executes extractions in shorter time and with less 
solvent than traditional extraction techniques. This technique uses conventional liquid 
solvents for extracting solid and semisolid samples. Due to elevated temperatures and 
pressures the efficiency of the extraction process is increased. The technology is completely 
automated. 
 
 
3.6  CELL CULTURE 
 
HL60 promyelocytic leukaemia cells and MCF7 breast cancer cells were purchased from 
ATCC. HL60 cells were grown in RPMI 1640 medium and MCF7 cells in Dulbecco’s 
Modified Eagle Medium (DMEM; GIBCO). The media were supplemented with 10 % heat-
inactivated fetal calf serum (FCS), 1% Glutamax and 1% Penicillin-Streptomycin. Cells were 
kept in humidified atmosphere containing 5% CO2 at 37°C. All media and supplements were 
obtained from Life Technologies. 
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3.6.1  Proliferation Assay - Proliferation inhibition analysis 
 
HL60 cells were seeded in T-25 tissue culture flasks or in 24-well plates at a concentration of 
1 x 10
5
 cells per ml cell culture medium and incubated with increasing concentrations of plant 
extracts or fractions. Cell counts and IC50 values were determined at 24 h and 72 h using a 
KX-21 N microcell counter (Sysmex Corporation). All experiments were done in triplicate. 
 
The percent of cell division progression compared to the untreated control was calculated as 
follows: 
 
[(C72 h + drug – C24 h +drug) / (C72 h – drug – C24 h – drug)] x 100 = % cell division 
C72 h + drug … cell number after 72 h of drug treatment 
C24 h + drug … cell number after 24 h of drug treatment 
C72 h - drug … cell number after 72 h without drug treatment 
C24 h - drug … cell number after 24 h without drug treatment 
 
3.6.2 Apoptosis Assay - Determination of cell death by Hoechst 33258/propidium 
iodide (HOPI) double staining 
 
To determine the type of cell death, HL60 cells were seeded in 24-well plates at a 
concentration of 1 x 10
5
 cells per ml cell culture medium and MCF7 cells were seeded in 96-
well plates at a concentration of 1 x 10
4
 per ml medium, grown for 24 hours. Then they were 
treated with increasing concentrations of extract or fractions (0.5 mg/ml, 1 mg/ml, 4 mg/ml, 
20 mg/ml and 0.4 µg/ml, 0.8µg/ml, 1.5 µg/ml, 3 µg/ml, respectively) for different periods of 
time (extract for 96 hours, fractions for 8 and 24 hours). 
 
Hoechst 33258 and propidium iodide were added to the cells at final concentrations of 5 and 2 
µg/ml, respectively. After 60 min of incubation at 37°C cells were examined on a Zeiss 
Axiovert fluorescence microscope equipped with a DAPI filter. Cells were photographed and 
analysed by visual examination to distinguish between apoptosis and necrosis [GRUSCH et 
al., 2002]. Cells were judged according to their morphology and the integrity of their cell 
membrane on the basis of propidium iodide exclusion. Those experiments were done in 
triplicate. 
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3.7 SEPARATION OF CHLOROPHYLL - Fractions F1/2 and 
F2/11,12,13,14,15,16 
 
Fractions F1/2 (eluate of P. odorata ASE - CH2Cl2 extract), fractionated by Vacuum Liquid 
Chromatography, and F2/11, F2/12, F2/13, F2/14, F2/15 and F2/16 (eluates of fraction F1/3), 
fractionated by Column Chromatography, were dispensed in two liquid solvents of different 
polarity, in CH2Cl2 and MeOH-H2O (1:1). 
 
1 g of fraction was dissolved in 150 ml CH2Cl2 (fraction in mg x 0.15) and afterwards in 150 
ml of methanol – water (1:1). The dichloromethane was evaporated at 40°C and 600-800 bar. 
Insoluble chlorophyll precipitated in the methanol–water phase and was eliminated by 
filtration. 
 
3.8  CHROMATOGRAPHY 
 
3.8.1  Thin Layer Chromatography (TLC) 
 
Stationary phase: silica gel plates 60 F254 (Merck, Darmstadt, Germany) 
Mobile phase: 
 
 
 
 
 
 
 
 
 
     
      Table 2  Composition of solvent system 1 – 6 
 
 
 
solvent system CHCl3:MeOH:H2O (ml) 
1 95:1.5:0.1 
2 90:3.5:0.2 
3 85:8:0.5 
4 80:10:1 
5 70:22:3.5 
6 60:40:10 
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Detection for solvent systems 1-6: After samples were separated, the TLC plates were 
analysed under UV366, UV254 and visible light, before and after spraying them with 
anisaldehyd sulphuric acid reagent (ASR). For visualisation of constituents , spraying the 
plates with ASR was followed by heating at 100°C for 5 min . The ASR compounds were 0.5 
ml anisaldehyd, 10 ml glacial acetic acid, 85 ml methanol and 5 ml H2SO4 (sulfuric acid). 
 
 
3.8.2  F1 Vacuum Liquid Chromatography (VLC) 
 
4 g of the CH2Cl2 extract was dissolved in 15 ml CH2Cl2. The thus obtained solution was 
mixed with 6 g silica gel and evaporated to dryness and stored in a desiccator for further use. 
To obtain a homogenous powder it was refined in a mortar and placed on top of a column 
(31x 4 cm), filled with 100 g silica gel. In order not to loose the powdered sample, it was 
covered with sea sand as ballast. 
 
1000 ml of each of the following mobile phases was used for fast elution with vacuum 
(table 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
solvent relation 
petroleum ether  
CHCl3  
CHCl3 : MeOH 9:1 
CHCl3 : MeOH 7:3 
CHCl3 : MeOH 5:5 
CHCl3 : MeOH 3:7 
CHCl3 : MeOH 1:9 
MeOH : H2O 7:3 
MeOH : H2O 1:1 
H2O  
Table 3  Mobile phases of VLC F1 (detailed relation) 
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3.8.3  FX Column Chromatography (CC) - fractionation of F1/2 
 
After chlorophyll was eliminated in the first step, the separation of fraction F1/2 was carried 
out on a 80x2 cm column, filled with 150 g silica gel. 410.6 mg of fraction F1/2 was 
dissolved in 6 ml chloroform and mixed with 8 g of silica gel. Afterwards the solvent was 
evaporated to dryness and the prepared fraction stored in a desiccator over night. After 
refining it in a mortar it was placed on top of the column and covered with sea sand. 
Screening was performed with solvent system 4 (80:10:1). 
 
For the elution of compounds three different mobile phases were used: 
430 ml CHCl3 : MeOH : H2O (100:10:1). Followed by 200 ml of CHCl3 : MeOH : H2O 
(90:10:0.1) and 286 ml of CHCl3 : MeOH : H2O (70:22:3.5). 
 
3.8.4  F2 Column Chromatography (CC) - fractionation of F1/3 
 
Chromatographic separation was performed on a 80x2 cm column, filled with 150 g silica gel. 
1.46 g of fraction F1/3 (CHCl3:MeOH 9:1) was dissolved in 9 ml chloroform and mixed with 
1.5 g silica gel. Then, the solvent was evaporated to dryness and stored in a desiccator over 
night. After refining it in a mortar it was placed on top of the column and covered with sea 
sand. A fluid reservoir for different solvents was fixed above the column and the following 
solvents, shown in table 4 below, were used for elution. The solvent MeOH : H2O (95:5) was 
passed through the column by applying vacuum. 
 
 
 
 
 
 
 
 
 
solvent relation amount (ml) 
CHCl3  500 
CHCl3 : MeOH : H2O 95 : 1.5 : 0.1 600 
CHCl3 : MeOH : H2O 90 : 3.5 : 0.2 562 
CHCl3 : MeOH : H2O 85 : 8 : 0.5 2000 
MeOH : H2O 95 : 5 500 
Table 4  Solvent systems of CC F2 
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3.8.5  F3 Column Chromatography (CC) - fractionation of F2/13 
 
30 mg of fraction F2/13 (after separation of chlorophyll) were dissolved in 2 ml CHCl3. The 
thus obtained solution was mixed with 430 mg silica gel and evaporated to dryness and it was 
stored in a desiccator over night. For receiving a homogenous powder it was refined in a 
mortar and placed on top of a column (98x1cm), filled with 75 g silica gel. The powder was 
covered with sea sand. 
 
The mobile phase was CHCl3:MeOH (95:5) for slower elution and therefore a more precise 
separation. 
 
3.8.6  F4 Reversed Phase - Solid Phase Extraction (SPE) – fractionation of F3/3 
 
The used stationary phase was a Bond Elut C18 cartridge (Column specification: 1210-2058; 
1 ml/50 mg/40 µm), which is of extreme retentive nature for non polar compounds and a 
benefit when unknown compounds vary widely in structure. 
 
 
 
 
 
First step was the conditioning of cartridge with MeOH. Then fraction F3/3 was dissolved in 
CHCl3 and eluted by vacuum as fraction F4/1. 
 
Afterwards the cartridge was eluted by vacuum with different solutions of MeOH and H2O 
(90 %, 80 % and 70% MeOH) and CHCl3:MeOH (1:1), respectively. Thereby, fractions F4/2, 
F4/3, F4/4 and F4/5 were obtained. In between each elution the cartridge was dried by 
vacuum for 2 minutes. 
Table X.  
 
Figure 5  SPE equipment: 
Bond Elut C18 cartridge on top (see the arrow), 
glass tray connected with vacuum pump 
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3.8.7  F5 Reversed Phase - Solid Phase Extraction (SPE) – fractionation of F4/1 
 
As stationary phase a Bond Elut C18 cartridge (Column specification: 1210-2058; 
1 ml/50 mg/40 µm) was used. 
 
First step was the conditioning of cartridge with MeOH. Then, fraction F4/1 was dissolved in 
CHCl3 and eluted by vacuum as fraction F5/1. 
 
Afterwards the cartridge was eluted by vacuum with two different solutions of MeOH and 
H2O (98 % and 96 % MeOH). Thereby, fractions F5/2 and F5/3 were obtained. By elution of 
CHCl3:MeOH (1:1) fraction F5/4 was gained. In between each elution the cartridge was dried 
by vacuum for 2 minutes. 
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3.9  WESTERN BLOTTING 
 
3.9.1  Preparation of lysates 
 
HL60 cells were seeded in a tissue culture flask at a concentration of 1 x 10
6
 cells per ml 
medium and incubated with 3 µg/ml fraction (F2/11, F2/13 and F3/4, respectively) for  0.5 h, 2 
h, 4h, 8h and 24 hours. At each time point, 2 x 10
6
 cells were harvested, placed on ice and 
centrifuged (1000 rpm, 4ºC, 4 min). Then, the supernatant (medium) was discarded and the 
pellet was washed twice with cold PBS (pH 7.2), and centrifuged (1000 rpm, 4 ºC, 4 min). 
 
The pellets lysed in 150 µl buffer containing 150 mM NaCl, 50 mM Tris ph 8.0, 1 % Triton 
X-100, 2.5 % 0.5 mM PMSF and PIC (Sigma, Schnelldorf, Germany). Debris was removed 
by centrifugation (12,000 rpm, 4 ºC, 20 min) and the supernatant was stored at -20°C until 
further analyses. 
 
3.9.2  SDS-PAGE and electrotransfer 
 
Equal amounts of lysate (protein samples) were loaded onto 10 % polyacrylamide gels. 
Proteins were electrophoresed (PAGE) at 120 volt (50 mA) for approximately 2 hours and 
then electroblotted onto PVDF membranes (Hybond P, Amersham, Buckinghamshire, UK) at 
100 Volt and 4ºC for 1 hour. To confirm equal sample loading, membranes were stained with 
Ponceau S. 
 
3.9.3  Immuno reaction 
 
After washing with TBS or PBS, the membranes were blocked for 1 hour in blocking solution 
containing 5 % skimmed milk in TBS and PBS with 0.5 % Tween 20, respectively, washed for 
30 min (changing the washing solution 5 times) in TBS/T or PBS/T, and incubated by gentle 
rocking with primary antibodies in blocking solution (dilution 1:500) at 4 ºC overnight. 
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Then, the membranes were washed in TBS/T or PBS/T (4 x for 10 min) and further incubated 
with the second antibody (peroxidase-conjugated anti-rabbit IgG or anti-mouse IgG, dilution 
1:2000), for 1 h at room temperature. The membranes were washed with TBS/T or PBS/T (4 x 
for 10 min) and the chemoluminescence (ECL detection kit, Amersham, Buckinghamshire, 
UK) was detected by exposure of the membranes to Amersham Hyperfilm
TM
 ECL. 
 
The antibody against Phospho-Cdc25A (S75) was from Abcam (Cambridge, MA, USA) and 
against Phospho-Cdc25A (S177) was from Abgent (San Diego, CA, USA). Anti-H2AX 
(pSer139) was from Calbiochem (San Diego, CA, USA) and the antibodies against Cleaved 
Caspase-3 (Asp175), Chk2, Phospho-Chk2 and Phospho-cdc2 (Tyr15) were from Cell 
Signaling (Danvers, MA, USA). 
 
The antibodies against Cdc2 p34 (17), Cdc25A (F-6), Cyclin D1 (M-20), PARP-1 (F-2) and α 
Tubulin (DM1A) were from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA) and the 
antibodies against Anti--Actin and Anti-acetylated Tubulin were from Sigma (St. Louis, 
MO, USA). 
 
 
3.9.3.1  Antibodies 
 
o Phospho-Cdc25A (S75) antibody (ab47279), polyclonal (Abcam) 
o Phospho-Cdc25A (S177) antibody, polyclonal (Agent) 
o Anti-H2AX (pSer139), polyclonal, No. DR1017 (Calbiochem) 
o Cleaved Caspase-3 (Asp175), #9661, polyclonal (Cell Signaling) 
o Chk2, #2662, polyclonal (Cell Signaling) 
o Phospho-Chk2 (Thr68), #2661, polyclonal (Cell Signaling) 
o Phospho-cdc2 (Tyr15) (10A11), #4539, monoclonal, Rabbit mAb, 
(Cell Signaling) 
o Cdc2 p34 (17): sc-54, monoclonal (Santa Cruz Biotechnology, Inc.) 
o Cdc25A (F-6): sc-7389, monoclonal (Santa Cruz Biotechnology, Inc.) 
o Cyclin D1 (M-20): sc-718, polyclonal (Santa Cruz Biotechnology, Inc.) 
o PARP-1 (F-2): sc-8007, monoclonal (Santa Cruz Biotechnology, Inc.) 
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o α Tubulin (DM1A): sc-32293, monoclonal (Santa Cruz Biotechnology, Inc.) 
o Anti--Actin, clone AC-15, mouse ascites fluid, No. A5441 (Sigma) 
o Anti-acetylated Tubulin, clone 6-11B-1, mouse ascites fluid, No. T6793 (Sigma) 
 
Pierce ECL Western Blotting Substrate Cat #32106 (Pierce) and Amersham Hyper films   
ECL – High performance chemiluminnescence film (GE Healthcare) was used. 
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4  RESULTS  AND  DISCUSSION 
 
 
4.1  EXTRACTION OF PLUCHEA ODORATA 
 
Dried plant material of Pluchea odorata was extracted in two different ways (scheme 1: 
CH2Cl2 extraction; scheme 2: CHCl3 extraction) to compare their anti-neoplastic activity in 
HL60 human leukemia cells. Subsequently, the more potent extract was compared with an 
accelerated extraction method (chapter 3.5, page 19). The following schemes (scheme 1 and 
scheme 2) detail the workflow and give an overview of the methodology for a better attribution 
of results. 
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4.1.1  Extraction with dichloromethane (CH2Cl2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1  Sequential extraction with petroleum ether and dichloromethane 
20g of dried powdered plant material were dissolved in 200 ml PE (1:10), extracted by ultrasonication at 
room temperature for 10 min and at 40 °C on a reflux water bath for 1 hour. Then, the solvent was filtrated 
through a round filter and the obtained filtrate was evaporated for storing. Retained plant material was dried 
over night. Then it was mixed with 200 ml (1:10) of CH2Cl2 and extracted again by ultrasonication at room 
temperature for 10 min and at 50 °C on a reflux-water bath for 1 hour. The solvent was filtrated through a 
round filter and the obtained filtrate was evaporated by a rotavapor until complete dryness. 
10 min sonicate 
20g plant material 
1. + 200ml 
(1:10) 
PE 
1 h on water bath 
filtering 
filtrate plant material 
evaporate 
 
1. PE extract 
2. CH2Cl2 extract 
2. + 200ml 
(1:10) 
CH2Cl2 
dissolve CH2Cl2 extract 
in EtOH  
for subsequent testing in 
HL60 leukemia cells 
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The dried CH2Cl2 extract of P. odorata (279.5 mg) was dissolved in 3 ml 96 % ethanol for 
subsequent testing. 
 
In a subsequent Proliferation test the CH2Cl2 extract of P. odorata extract was compared with 
equal amounts CHCl3 extract to evaluate the bioactive properties contained in the different 
extract types. Scheme 2 (page 32) shows the workflow of preparing the CHCl3 extract of      
P. odorata. 
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4.1.2  Extraction with 
chloroform (CHCl3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
10 min. sonicate 
20g plant material 
+ 200 ml (1:10) MeOH 
evaporate 
 
MeOH extract 
dissolve in 100 ml 
MeOH:H2O (9:1) dissolve CHCl3 extract 
in EtOH 
for subsequent testing in 
HL60 leukemia cells 
 
defat with PE (3x) 
PE extract (store) Aqueous MeOH fraction 
partition with 200 ml CHCl3 (1x) 
+ H2O (1:1) 
CHCl3 extract Aqueous extract 
(evaporate and store) 
wash with 200 ml NaCl 1% 
spike with Na2SO4 sicc. 
filtrate 
CHCl3 extract 
evaporate 
1h on water bath 
filtering 
filtrate plant material 
3
2
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Scheme 2  Extraction with CHCl3 
20g of dried powdered plant material were dissolved in 200 ml MeOH (1:10), extracted by ultrasonication at 
room temperature for 10 min and at 79 °C on a reflux water bath for 1 hour. Then, the solvent was filtrated 
through a round filter and the obtained filtrate was evaporated until dryness and redissolved in 100 ml 
MeOH:H2O (9:1). 
 
The retained MeOH extract was degreased with 100 ml PE. The mixture of immiscible liquids was put into a 
separating funnel, shaken and allowed to settle for three times. The obtained PE extract was evaporated and 
stored. The aqueous MeOH fraction was mixed with 100 ml H2O (1:1). By using a separating funnel the partition 
with 200 ml CHCl3 was carried out. 
 
The aqueous extract was evaporated and stored. The CHCl3 extract was washed twice with 200 ml saline 
solution (NaCl 1 %) and spiked with Na2SO4 (Natrium sulfuricum siccatum). After filtering through a round 
filter the chloroform extract was evaporated. 
 
 
 
The dried CHCl3 extract of P. odorata (260 mg) was dissolved in 1.5 ml 96 % ethanol for 
subsequent testing. The bioactivity of the CHCl3- and CH2Cl2 extracts was compared by a 
Proliferation assay. 
 
 
4.2 ANTI-PROLIFERATIVE ACTIVITY OF P. ODORATA EXTRACTS 
 
To compare the anti-neoplastic activity of the CH2Cl2- and CHCl3 extracts, the different 
extract types were tested in HL60 leukemia cells. Subsequent investigations were performed 
with the more potent extract type. 
 
The cells were incubated with increasing concentrations (mg amounts of dried plant material 
before extraction) of the dissolved extract types. As shown in figure 6, both extracts indicated 
anti-proliferative effects. Whereas the stronger anti-proliferative activity was observed in the 
CH2Cl2 extract, which inhibited growth by ~ 75% at 0.5 mg plant material/ml, the inhibition 
of growth of CHCl3 extract was weaker, approximately 60% at 0.5 mg plant material/ml after 
72 hours of incubation. 
 
Therefore, the CH2Cl2 extract was also tested by an apoptosis assay in MCF7 breast cancer 
cells, in which the cell death rate was more than 50% when treated with a concentration of 4 
mg/ml after 96 hours (figure 7). 
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Figure 6  Anti-proliferative effect of CH2Cl2 - and CHCl3 extract of P. odorata 
HL60 cells were seeded into T-25 tissue culture flasks (1 x 10
5 
 cells/ml), incubated with 0.5, 1, 4 and 20 
mg/ml of CH2Cl2 and CHCl3 extract, respectively (mg-amounts relate to dried plant material before 
extractions) for 72 hours. Controls received 0.15 % to 0.30 % EtOH which was the highest EtOH 
concentration, cells had to experience in association with highest extract concentration. Equalization of 
EtOH was done in all samples to achieve same solvent conditions. Cells were counted after 24, 48 and 72 
hours of treatment. 
The percentage of proliferation between 24 and 72 hours was determined in comparison to control. 
Experiments were done in triplicate. Asterisks indicate significance compared to untreated control 
(p<0.05) and error bars SEM (see methods, page 20). 
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Figure 7  Induction of apoptosis by the CH2Cl2 extract of P. odorata 
MCF7 cells were seeded in 96-well plates. Cells were allowed to attach over night and then they were incubated 
with 0.5, 1, 4 and 20 mg/ml of plant CH2Cl2 extract (mg-amounts relate to dried plant material before 
extractions) for 96 hours. Then, cells were double stained with Hoechst 33258 and propidium iodide and 
examined under the microscope with UV light connected to a DAPI filter. Nuclei with morphological changes 
which indicated apoptosis or necrosis were counted and percentages of vital, apoptotic and necrotic cells were 
calculated. Experiments were done in triplicate. Asterisks indicate significance compared to untreated control 
(p<0.05) and error bars SEM (see methods, page 20). 
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4.2.1  Stock calculation – Pluchea odorata 
 
Table 5 shows the extract weight in mg derived from 20 g freeze dried plant for the two 
different solvent types (dichloromethane, chloroform) and the extract amount in µg 
corresponding to 1 mg plant. 
 
Four different concentrations were used to perform Proliferation assays: 0.5 mg/ml, 1 mg/ml, 
4 mg/ml, 20 mg/ml (dried plant weight in mg/ml medium). These concentrations 
corresponded to different amounts of dried extract in µg/ml medium. 
 
The plant extracts were dissolved in different amounts of EtOH (3ml or 1.5ml, respectively). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5  Stock calculation of  P. odorata CH2Cl2 and CHCl3 extract 
Extract weight derived from 20 g dried plant material, extract amount corresponding to 1 mg plant and amounts 
of dried extract corresponding to different concentrations (dried plant weight/ml medium) of Proliferation 
assays. 
solvent extract weight (mg) 
derived from 20 g dried plant 
extract (µg) corresponding to 
1 mg plant 
dichloromethane 279.5 13.98 
chloroform 260.0 13.00 
extract type 
concentration 
mg dried plant weight/ml 
medium 
µg dried extract/ml medium 
dichloromethane 0.5 6.98 
1 13.97 
4 55.89 
20 279.48 
chloroform 0.5 6.50 
1 13.00 
4 52.00 
20 260.00 
           37 
 
4.3 EXTRACTION OF P. ODORATA with CH2Cl2 by ASE 200 – 
Comparison with common CH2Cl2 extraction 
 
To compare the bio-activity of the conventional CH2Cl2 extract with the ASE - CH2Cl2 extract 
the lyophilised and milled plant material of P. odorata, 17.5 g plant powder, was extracted by 
ASE 200. The first cycle was performed with PE to eliminate chlorophyll and lipids, 
afterwards the same plant material was extracted three times with CH2Cl2. The supernatant 
was evaporated and the weight of the obtained dried extract (630 mg) was measured. The 
extraction was performed with a pressure of 150 bar and at 40°C. 
 
For testing the ASE CH2Cl2 extract cells were incubated with increasing concentrations 
extract (shown in table 6 below). For further investigations an additional amount of   192 g 
lyophilised and milled plant material was extracted by ASE. 
 
 
4.3.1  Stock calculation – Pluchea odorata ASE - CH2Cl2 extract 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6  Stock calculation of  P. odorata ASE - CH2Cl2 extract 
Extract weight derived from 17.5 g dried plant material, extract amount corresponding to 1 mg plant and 
amounts of dried extract corresponding to different concentrations (dried plant weight/ml medium) of 
Proliferation assay. 
solvent 
extract weight (mg) 
derived from 17.5g dried 
plant 
extract (µg) corresponding to 
1mg plant 
dichloromethane 630 36 
extract type 
concentration 
mg dried plant weight/ml 
medium 
µg dried extract/ml medium 
dichloromethane 0.028 1 
0.139 5 
0.278 10 
0.417 15 
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The extraction by ASE 200 Accelerated Solvent Extractor was more efficient. In comparison 
with the conventional CH2Cl2 extraction the obtained extract amount was higher. The 
amounts are shown in table 7: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Table 7  Comparing obtained amount of dried extract by ASE and conventional extraction, respectively. 
 
 
 
Less time for extraction was needed by ASE and the anti-proliferative activity of the 
conventional CH2Cl2 extract and the ASE - CH2Cl2 extract was similar (shown in figures 8 
and 9). Because an extract concentration of 15 µg/ml or 13.97 µg/ml, respectively, inhibited 
HL60 cells proliferation by approximately 70 % after 72 hours. Therefore further extraction 
of P. odorata with dichloromethane was done by ASE. 
 
 
dried plant material 
in g 
obtained dried extract 
in g 
obtained dried extract 
in % of dried plant 
powder 
extraction by ASE: 
192 g 
 
4 g 
 
 2.08 % 
                  17.5 g       0.630 g 3.6 % 
conventional extraction: 
20 g 
 
     0.279 g 
 
1.4 % 
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4.3.2 Anti-proliferative activity of P. odorata ASE extract vs. conventional extract 
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Figure 8  Anti-proliferative effect of ASE - CH2Cl2 extract of P. odorata 
HL60 cells were seeded into T-25 tissue culture flasks (1 x 10
5 
 cells/ml), incubated with 1, 5, 10 and 15 µg/ml 
of ASE - CH2Cl2 extract for 72 hours. Control received 0.18 % EtOH which was the highest EtOH 
concentration, cells had to experience in association with highest extract concentration. Equalization of EtOH 
was done in all samples to achieve same conditions. Cells were counted after 24, 48 and 72 hours of treatment. 
The percentage of proliferation between 24 and 72 hours was determined in comparison to control. Experiments 
were done in triplicate. Asterisks indicate significance compared to untreated control (p<0.05) and error bars 
SEM (see methods, page 20). 
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Figure 9  Anti-proliferative effect of CH2Cl2 extract of P. odorata 
HL60 cells were seeded into T-25 tissue culture flasks (1 x 10
5 
 cells/ml), incubated with 0.5, 1, 4 and 20 mg/ml 
of CH2Cl2 extract (mg-amounts relate to dried plant material before extractions) for 72 hours. Control received 
0.30 % EtOH which was the highest EtOH concentration, cells had to experience in association with highest 
extract concentration. Equalization of EtOH was done in all samples to achieve same conditions. Cells were 
counted after 24, 48 and 72 hours of treatment. 
The percentage of proliferation between 24 and 72 hours was determined in comparison to control. Experiments 
were done in triplicate. Asterisks indicate significance compared to untreated control (p<0.05) and error bars 
SEM (see methods, page 20). 
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4.3.3  Testing of different TLC systems – fingerprint of CH2Cl2 extract 
 
To evaluate an adequate TLC system, 0.5 g of dried P. odorata CH2Cl2 extract was dissolved 
in 2 ml CH2Cl2. Spots of 20µl were applied on silica gel plates. To obtain the best separation 
6 different solvent systems (less polar to polar) were tested (conditions see chapter 3.8.1, 
p21). Detection of each solvent system was performed under UV254 with or without ASR. 
 
Solvent system 5 (CHCl3:MeOH:H2O; 70ml:22ml:3.5ml) showed a suitable separation of the 
rather apolar CH2Cl2 extract. Hence, this TLC solvent system was used for further TLC 
analysis (figure 10). 
 
 
 
 
Figure 10  Above: P. odorata CH2Cl2 extract; solvent system 1-6; under UV254 without reagent 
        Below: P. odorata CH2Cl2 extract; solvent system 1-6; under UV254 with ASR 
 
 
1 
2 
3 2 4 
3 4 
6 
5 6 
5 
1 
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4.4  FRACTIONATION of ASE - CH2Cl2 EXTRACT of P. ODORATA 
 
192 g dried and milled plant material of P. odorata was extracted with CH2Cl2 by ASE (see 
page 19). The obtained ASE - CH2Cl2 extract (4 g) was fractionated by VLC (F1, see page 
22). The 10 resulting fractions (F1/1 – F1/10) were tested with regard to their anti-
proliferative activity, whereby fraction F1/2 (apolar CHCl3 – fraction) and fraction F1/3 
(apolar CHCl3:MeOH 9:1- fraction) showed significant effects. 
 
The fractionation of chlorophyll-free fraction F1/2 followed by CC (FX, see page 23), finally 
resulting in 7 fractions (potent fractions FX/A,C,D,E,F and inactive FX/B,FX/G). 
Investigations on fraction F1/2 stopped at this point, because it turned out that the presence or 
absence of chlorophyll did not make a difference regarding the anti-proliferative activity. 
 
Fraction F1/3 was further fractionated by CC (F2, see page 23). Its 21 resulting fractions 
(F2/1 – F2/21) were tested concerning anti-proliferative activity, whereby fractions 
F2/11,12,13,14,15 and 16 (solvent relation CHCl3:MeOH:H2O 95:1.5:0.1 to 90:3.5:0.2, 
apolar range) showed significant growth inhibition. 
 
Then, chlorophyll was separated from fractions F2/11 – F2/16, because it obscured the 
barmarks on TLC`s. From a quantitative point of view the biggest fraction, F2/13, was 
fractionated by CC (F3, see page 24) and the 5 obtained fractions (F3/1 – F3/5) were tested by 
Proliferation assay which showed the significant anti-proliferative activity of fractions F3/3 
and F3/4. 
 
Therefore fraction F3/3 was further fractionated by SPE (F4, see page 24), whereby 5 
fractions were obtained. Fraction F4/1 and F4/2 were reunified and again fractionated by SPE 
(F5, see page 25). The steps of fractionation ended in two fractions, F5/1 and F5/2. The 
following scheme (see page 42f) overviews and details the workflow of fractionation steps, 
whereby the most active fractions are signed with an asterisk. 
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4.4.1  Fractionation – overview   
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Figure 11  Fractionation steps - overview 
 
See page 24 
(F4) 
See page 25 
(F5) 
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4.4.2  F1 Vacuum Liquid Chromatography (VLC) 
 
4 g of the CH2Cl2 extract of P. odorata was fractionated by VLC (see methods, p 22). 1000 
ml of each of the mobile phases (solvents listed in table 8) was used for fast elution with 
vacuum. Solvent systems differed from TLC solvent systems due to different conditions 
between the separation techniques. 
 
The 10 resulting fractions were analysed by TLC (figure 13). Ongoing they were evaporated 
to dryness and summed up, yielded a total weight of 3.95g (table 8), thus 98.8 % of starting 
material (4 g) was recovered. The biggest obtained fraction was the apolar CHCl3
 
- fraction 
F1/2 (1.36 g) and the apolar (CHCl3:MeOH 9:1) F1/3 (1.46 g). Resulting fractions (g) are also 
shown in a bar graph (figure 12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
fraction solvent relation yield (g) 
F1/1 PE  0.21 
F1/2 CHCl3  1.36 
F1/3 CHCl3 : MeOH 9:1 1.46 
F1/4 CHCl3 : MeOH 7:3 0.45 
F1/5 CHCl3 : MeOH 5:5 0.09 
F1/6 CHCl3 : MeOH 3:7 0.14 
F1/7 CHCl3 : MeOH 1:9 0.09 
F1/8 MeOH : H2O 7:3 0.08 
F1/9 MeOH : H2O 1:1 0.05 
F1/10 H2O  0.02 
   total    3.95 
Table 8  Obtained fractions of VLC in gram and corresponding mobile phases 
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4.4.2.1  TLC of fractions F1/1 to F1/10 
 
For comparison 20 µl of each fraction was applied on a silica gel plate. 
Solvent system 5 (CHCl3:MeOH:H2O 70:22:3.5 ml) was used as mobile phase. After samples 
were separated, the TLC plate was sprayed with ASR, followed by heating at 100°C for 5 min 
to facilitate visualization, and analysed under UV254 (see chapter 3.8.1, methods page 21). 
 
 
 
 
 
Figure 13  TLC: P. odorata CH2Cl2 extract (P.o.); fractions F1/1 – F1/10; detection: ASR under UV254; solvent 
system 5; by using the solvent systems PE and CHCl3  all apolar components were eluted; by elution with 
CHCl3:MeOH 9:1 most of components were obtained in apolar fraction F1/3; only few components seemed to be 
little more polar (see F1/5 to F1/10). 
 
P.o.   F1/1    F1/2   F1/3   F1/4   F1/5   F1/6   F1/7   F1/8   F1/9   F1/10 
Figure 12  The type and amount of obtained VLC fractions (in gram) 
        of the P. odorata ASE – CH2Cl2 extract 
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4.4.2.2  Anti-proliferative activity of fractions F1/1 to F1/10 
 
To test the anti-proliferative activity of fractions F1/1 to F1/10 they were dissolved in DMSO 
and fraction F1/10 in DMSO, distilled water and EtOH (table 9). Fractions varied in 
solubility. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HL60 cells were seeded in  24-well plates at a concentration of 1 x 10
5
 cells per ml, and 
incubated for 72 hours with 10 µg/ml of each fraction. Cells were counted after 24, 48 and 72 
hours. 
 
Fraction F1/3 (CHCl3:MeOH 9:1) showed a significant growth inhibition up to 60 % at a 
concentration of 10µg/ml. The starting ASE – CH2Cl2 extract of P. odorata (10µg/ml) 
showed an effective growth inhibition around 40 % (see figure 8, p39). Thus, the bio-activity 
of F1/3 increased by 20 %. After 48 hours of incubation also fractions F1/2, F1/4 and F1/5 
were active in comparison to control (figure 14; figure 15). Based on these results 
fractionation of F1/2 and F1/3 followed (see page 48-59). 
fraction stock for proliferation assay 
F1/1 1370µg/ 330µl DMSO 
F1/2 1300µg/ 240µl DMSO 
F1/3 1100µg/ 160µl DMSO 
F1/4 1500µg/ 80µl DMSO 
F1/5 1000µg/ 80µl DMSO 
F1/6 1260µg/ 80µl DMSO 
F1/7 1150µg/ 80µl DMSO 
F1/8 1120µg/ 80µl DMSO 
F1/9 1000µg/ 80µl DMSO 
F1/10 1100µg/ 60µl DMSO + 100µl Aqua dest. + 30µl EtOH 
Table 9  Stock solutions of F1/1 – F1/10 for Proliferation assay 
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Figure 14  Anti-proliferative effect of fractions F1/1 to F1/10 
HL60 cells were seeded into 24-well plates (1 x 10
5 
 cells/ml), incubated with 10 µg/ml of each fraction for 72 
hours. Control received 0.5 % DMSO which was the highest DMSO concentration, cells had to experience in 
association with highest fraction concentration. Equalization of DMSO was done in all samples to achieve same 
conditions. Cells were counted after 24, 48 and 72 hours of treatment. 
The percentage of proliferation between 24 and 72 hours was determined in comparison to control. Experiments 
were done in triplicate. Asterisks indicate significance compared to untreated control (p<0.05) and error bars 
SEM (see methods, page 20). 
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Figure 15  Anti-proliferative effect of fractions F1/1 to F1/10 (cell count) 
HL60 cells were seeded into 24-well plates (1 x 10
5 
 cells/ml), incubated with 10 µg/ml of each fraction for 72 
hours. Control received 0.5 % DMSO which was the highest DMSO concentration, cells had to experience in 
association with highest fraction concentration. Equalization of DMSO was done in all samples to achieve same 
conditions. Cells were counted after 24, 48 and 72 hours of treatment and count of cells is shown as bar chart. 
Experiments were done in triplicate. Asterisks indicate significance compared to untreated control (p<0.05) and 
error bars SEM (see methods, page 20). 
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4.4.3  FX Column Chromatography (CC) – fractionation of F1/2 
 
4.4.3.1  Separation of chlorophyll of fraction F1/2 
 
1.36 g of F1/2 was dissolved in 204 ml CH2Cl2 and then 204 ml of methanol-water (1:1) were 
added. The CH2Cl2 was evaporated at 40°C and 600-800 bar. The chlorophyll precipitated in 
the methanol-water phase and was filtered off under vacuum (see chapter 3.7, p21). The 
weight of the obtained dried fraction without chlorophyll was measured (410.6 mg). 
Therefore, 30.2 % of the initial fraction contained chlorophyll-free bioactitiy. 
 
 
 
Figure 16  TLC:  A: F1/2 with chlorophyll; detection: under UV366; solvent system 4 
                     B: F1/2 without chlorophyll; detection: under UV366; solvent system 4 
 
 
4.4.3.2  Fractionation of chlorophyll-free fraction F1/2 by CC 
 
410.6 mg of fraction F1/2 were dissolved in 6 ml chloroform and mixed with 8 g of silica gel. 
Afterwards the solvent was evaporated to dryness and stored in a desiccator for further use. 
After refining it in a mortar it was placed on top of the 80x2 cm column, filled with 150 g 
silica gel, and covered with sea sand. 
 
For the elution of all contained compounds a gradient from apolar to middle polar was 
chosen. Therefore three different mobile phases were used: The first phase was 430 ml of 
CHCl3:MeOH:H2O (100:10:1), whereby the elution rate was approximately 7 ml solvent per 
30 minutes. This was followed by the second phase consisting of 200 ml CHCl3:MeOH:H2O 
  A        B 
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(90:10:0.1) and finally 286 ml of the third middle polar phase consisting of 
CHCl3:MeOH:H2O (70:22:3.5). The last two mobile phases were passed through the column 
by applying vacuum. 
 
85 resulting fractions were collected and every fifth was tested by TLC (figure 17) to obtain a 
representative transect of fractions. Since distinct bar mark patterns occurred in the fractions 
FX/15 to FX/40 each single fraction was retested again by TLC using solvent system 4 
(CHCl3:MeOH:H2O 80:10:1) (figure 18). After comparing every fraction with each other, 
similar-locking fractions were pooled, finally resulting in 7 fractions (FX/A, B, C, D, E, F, G) 
(figure 19, 20, 21). 
 
Screening was performed with solvent system 4 (80:10:1). For detection UV366, UV254 and 
visible light were used, before and after spraying the plate with anisaldehyd sulphuric acid 
reagent (ASR). 
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4.4.3.2.1  TLC of fractions FX/1 to FX/85 
 
 
 
 
 
 
 
 
 
 
Similarly looking fractions (based on similar bar mark patterns), that were obtained from CC-
fractionation of F1/2, were recombined as follows: 
 
 
 
 
 
 
 
 
 
 
obtained fractions recombined as fraction: 
  1 - 21 FX/A 
22 - 25 FX/B 
26 - 29 FX/C 
30 - 32 FX/D 
33 - 50 FX/E 
51 - 68 FX/F 
69 - 85 FX/G 
1      5      10     15     20     25     30      35    40      41       45         50        51       55       60       65      70      75      80       85 
Figure 17  TLC: Fractions FX/1 – FX/85; detection: ASR under UV366; solvent system 4; 
every fifth fraction was tested. The apolar fractions 20, 25, 30 and 35 contained different compounds. 
No bar marks were detected after fraction FX/36 (see figure 18 below). 
  16    17    18    19    20    21   22     23    24     25   26    27   28    29     30     31      32      33     34     35     36      37     38     39 
Figure 18  TLC: Apolar fractions FX/16 – FX/39 in detail; detection: ASR under UV366; solvent 
system 4; similarly looking fractions were pooled (containing one or more identical bar marks), 
finally resulting in 7 fractions, eluted by an apolar solvent system (CHCl3:MeOH:H2O 100:10:1) 
(table 10 below). 
Table 10  Nomenclature of recombined fractions 
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4.4.3.2.2  TLC of fractions FX/A-G 
 
The obtained 85 fractions, that were finally pooled in 7 fractions FX/A, B, C, D, E, F and G 
were reanalysed by TLC. For visualization, bar marks of each fraction were detected by 
different methods and wave lengths (see figures 19, 20, 21 below). 
 
4.4.3.2.2.1  Fractions FX/A – G detected under UV254, UV366 and under UV366 after  
                     spraying with ASR 
 
              
 
                   254nm            366nm       366nm; ASR 
 
 
 
 
 
 
 
 
 
 
 
The anti-proliferative activity of FX/A, FX/C, FX/D, FX/E and FX/F showed an inhibition of 
growth around 100 % at a concentration of 10µg/ml (figure 22, page 53). Fraction FX/B 
inhibited proliferation for around 30 %. The TLC pattern shows differences in main 
components of these fractions. 
   A   B    C     D     E     F    G A    B    C     D     E     F    G 
Figure 19  TLC: Fractions 
FX/A – G; detection: under 
UV254; solvent system 4; 
using this detection method, 
bar marks of fraction A, B and 
C didn´t appear separated. No 
bar marks were visible in 
fraction F and G. 
Figure 21  TLC: Fractions 
FX/A – G; detection: ASR 
under UV366; solvent system 4 
using this detection method, 
contained compounds of 
fractions are plainly visible. 
Figure 20  TLC: Fractions 
FX/A – G; detection: under 
UV366; solvent system 4 
using this detection method, 
fraction A and B seemed to 
have an identical blue shining 
compound. Fraction C, D and 
E showed a blurred pattern. 
A luminous compound was 
visible in fraction G and     
the same ones, lower 
concentrated and therefore 
poor bright, in fraction F. 
   A   B   C     D    E     F   G 
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4.4.3.3  Anti-proliferative activity of fractions FX/A - FX/G 
 
For testing the anti-proliferative activity of fractions FX/A to FX/G, they were first dissolved 
in CHCl3 stock solution. Then the volume, which contained 1 mg fraction, was transfered into 
a reaction vial (table 11), dried under air stream and dissolved in   500 µl DMSO, resulting in 
working stocks of 2 µg/µl for each fraction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
To determine the anti-proliferative effect of the fractions FX/A – FX/G, HL60 cells were 
seeded in 24-well plates at a concentration of 1 x 10
5
 cells per ml, and incubated for 72 hours 
with 10 µg/ml of each fraction. Cells were counted after 24, 48 and 72 hours. 
 
Fractions FX/A, FX/C, FX/D, FX/E and FX/F inhibited HL60 growth up to nearly 100 % at a 
concentration of 10 µg/ml. In comparison, fraction FX/B inhibited proliferation only by 30 %. 
Due to changing affinity of potent principles to the stationary phase fraction FX/B was 
different and hereby less active (figure 22). 
 
fraction yield (mg)/ CHCl3 (µl) 
CHCl3 stock solution 
volume (µl) containing 
1 mg fraction 
FX/A 40.6/1500 37 
FX/B 153.5/2000 13 
FX/C 47.9/1200 25 
FX/D 24.8/1500    60.5 
FX/E 9.2/1000 109 
FX/F 4.0/1000 250 
FX/G 6.7/1000 150 
Table 11  Prepared stock solutions of FX/A – FX/G for Proliferation assay 
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The starting material, the P. odorata ASE - CH2Cl2 extract, showed an inhibition of 
proliferation of 40 % at a concentration of 10µg/ml (see figure 8, p39). After separation of the 
chlorophyll content, which was about 2/3 of this fraction (F1/2), the anti-proliferative activity 
was fully maintained and found in 5 different fractions (FX/A, FX/C – FX/F). Thus, most of 
the non-active content was eliminated and the active principle became increasingly purified.  
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Figure 22  Anti-proliferative effect of fractions FX/A to FX/G 
HL60 cells were seeded into 24-well plates (1 x 10
5 
 cells/ml), incubated with 10 µg/ml of each fraction for 72 
hours. Control received 0.5 % DMSO which was the highest DMSO concentration, cells had to experience in 
association with highest fraction concentration. Equalization of DMSO was done in all samples to achieve same 
conditions. Cells were counted after 24, 48 and 72 hours of treatment. 
The percentage of proliferation between 24 and 72 hours was determined in comparison to control. Experiments 
were done in triplicate. Asterisks indicate significance compared to untreated control (p<0.05) and error bars 
SEM (see methods, page 20). 
 
 
 
4.4.4  F2 Column Chromatography (CC) - fractionation of F1/3 
 
In course of the first fractionation of P. odorata ASE – CH2Cl2 extract by VLC, 10 fractions 
(F1/1 – F1/10) were obtained and tested for anti-proliferative effect. Thereby fraction F1/3 
was the most potent one after 72 hours of incubation (conc. 10 µg/ml) (figure 14, p 47) and 
contained the highest amount of obtained material (1.46 g). 
 
Furthermore, treatment with fractions F1/2 and F1/4 showed decreased the cell numbers in 
comparison to control, but the obtained amount of material were less (1.36 and 0.45 g, 
respectively), than for F1/3. Consequently the fractionation of F1/3 (1.4 g) followed. 
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A fluid reservoir for different elution solvents was fixed above the fractionation column (table 
12 below). The passage of the first four mobile phases was by gravity, and the fifth mobile 
phase MeOH:H2O (95:5) was passed through the column by applying vacuum. 
 
Some of the resulting 24 fractions (F2/19+20; F2/21+22+23) were pooled again, because they 
exhibited similar bar mark patterns. Then, these resulting 21 fractions were evaporated to 
dryness and the fraction weight was determined, which added up to 1.76 g (table 13, page 56). 
The fact that more material was regained after fractionation (1.76g) compared to the input 
(1.40g) is most likely due to minimal washout of column material. 
 
 
 
 
 
 
 
 
 
 
 
 
Due to the apolar property of the starting material, fraction F1/3, the chosen gradient for 
mobile phases used for the subsequent fractionations (obtaining fractions F2/1 – 24) was also 
in an apolar range in the beginning to less polar MeOH:H2O 95:5 at the end. 
 
 
4.4.4.1  TLC of fractions F2/1- 24 
 
The obtained 24 fractions, that were finally pooled in 21 fractions, were analysed by TLC. 
Screening was performed with solvent system 4 (80:10:1). For detection UV366 was used, 
before and after spraying the plate with ASR (figures 23 and 24). 
 
mobile phase relation amount (ml) 
CHCl3  500 
CHCl3 : MeOH : H2O 95 : 1.5 : 0.1 600 
CHCl3 : MeOH : H2O 90 : 3.5 : 0.2 562 
CHCl3 : MeOH : H2O 85 : 8 : 0.5 2000 
MeOH : H2O 95 : 5 500 
Table 12  Mobile phases of the fractionation of F1/3 
 
  
 
 
4.4.4.1.1  TLC of F2/1 – 24 
 
 
 
 
 
 
 
 
 
 
 
Figure 23  Fractions F1/3; F2/1-24; solvent system 4; under UV366 without ASR 
Chlorophyll is luminous red, all fractions differs in main compounds and concentration, respectively. All obtained fractions followed an 
apolar gradient, except fraction F2/24 was eluted by the middle polar solvent system MeOH:H2O 95:5. 
Fractions F2/11 to F2/16 showed the highest and similar anti-proliferative activity, but TLC pattern shows differences in main compounds. 
 
 
 
 
 Figure 24  Fractions F1/3, F2/1-24; solvent system 4; under UV366 with ASR 
                   Some bar marks are covered by chlorophyll, whereby visualization with ASR facilitates improved analysis. 
  F1/3    F2/1   F2/2    F2/3   F2/4   F2/5   F2/6    F2/7   F2/8  F2/9   F2/10  F2/11  F2/12  F2/13  F2/14  F2/15  F2/16  F2/17  F2/18  F2/19  F2/20  F2/21  F2/22  F2/23  F2/24 
  F1/3   F2/1    F2/2   F2/3   F2/4   F2/5   F2/6    F2/7   F2/8    F2/9   F2/10  F2/11  F2/12  F2/13   F2/14  F2/15  F2/16  F2/17  F2/18  F2/19  F2/20  F2/21  F2/22  F2/23  F2/24 
5
5
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4.4.4.2  Obtained fractions F2/1 to F2/21 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
fraction solvent relation yield 
(mg) 
F2/1 CHCl3  32.5 
F2/2   30.5 
F2/3   12.2 
F2/4 ▼  54.2 
F2/5   17.8 
F2/6   26.4 
F2/7 CHCl3:MeOH:H2O 95 : 1.5 : 0.1 67.2 
F2/8   24.8 
F2/9 ▼  48.5 
F2/10   32.9 
F2/11   113.2 
F2/12 CHCl3:MeOH:H2O 90 : 3.5 : 0.2 90.7 
F2/13   170.6 
F2/14   88.6 
F2/15 ▼  26.3 
F2/16   148.5 
F2/17   44.1 
F2/18 CHCl3:MeOH:H2O 85 : 8 : 0.5 64.9 
F2/19  
▼ 
 184.6 
F2/20  268.0 
F2/21 MeOH:H2O 95 : 5 213.0 
   total                1,760.0 mg 
Table 13  Obtained 21 fractions in mg and correlated solvent systems 
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4.4.4.3  Anti-proliferative activity of fractions F2/1 to F2/21 (including chlorophyll) 
 
For the preparation of the stock solutions to be tested in the Proliferation assay, fractions 
F2/1-21 were dissolved in DMSO and centrifuged at 12,000 rpm for 5 min. to precipitate 
unsoluble debris. The fractions were divided into 5 groups (A, B, C, D, E) and tested in 
separate experiments to avoid biases and to assess the reproducibility of the fraction types and 
of the test system (table 14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
fraction stock for proliferation 
assay 
A1 = F2/1 1.06 mg/300µl DMSO 
A2 = F2/6 1 mg/300µl DMSO 
A3 = F2/11 1 mg/400µl DMSO 
A4 = F2/16 1.21 mg/300µl DMSO 
A5 = F2/21 1.09 mg/300µl DMSO 
B1 = F2/2 0.98 mg/400µl DMSO 
B2 = F2/7 1.18 mg/300µl DMSO 
B3 = F2/12 1.15 mg/400µl DMSO 
B4 = F2/17 1.16 mg/300µl DMSO 
C1 = F2/3 0.76 mg/400µl DMSO 
C2 = F2/8 0.60 mg/300µl DMSO 
C3 = F2/13 1.10 mg/400µl DMSO 
C4 = F2/18 1.25 mg/400µl DMSO 
D1 = F2/4 1.17 mg/300µl DMSO 
D2 = F2/9 1 mg/300µl DMSO 
D3 = F2/14 1.14 mg/300µl DMSO 
D4 = F2/19 1.07 mg/300µl DMSO 
E1 = F2/5 1.11 mg/300µl DMSO 
E2 = F2/10 0.64 mg/300µl DMSO 
E3 = F2/15 0.99 mg/300µl DMSO 
E4 = F2/20 1.61 mg/300µl DMSO 
Table 14  Prepared stock of F2/1 to F2/21 for Proliferation assay 
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To determine the anti-proliferative effect of the fractions F2/1 to F2/21 HL60 cells were 
seeded in 24-well plates at a concentration of 1 x 10
5
 cells per ml. Cells were incubated for 72 
hours with 10 µg/ml per fraction sample. The DMSO concentration was adjusted for every 
sample to 0.5 % (correlated with 10 µg/ml). 
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Figure 25  Anti-proliferative effect of fractions F2/1 to F2/21 (including chlorophyll) 
HL60 cells were seeded into 24-well plates (1 x 10
5 
 cells/ml), incubated with 10 µg/ml of each fraction for 72 
hours. Control received 0.5 % DMSO which was the highest DMSO concentration, cells had to experience in 
association with highest fraction concentration. Equalization of DMSO was done in all samples to achieve same 
conditions. Cells were counted after 24, 48 and 72 hours of treatment. 
The percentage of proliferation between 24 and 72 hours was determined in comparison to control. Experiments 
were done in triplicate. Asterisks indicate significance compared to untreated control (p<0.05) and error bars 
SEM (see methods, page 20). 
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Fractions F2/11, F2/12, F2/13 and F2/15 showed an effective growth inhibition up to nearly 
100 %, F2/16 up to 95 % and F2/14 up to 80 % at a concentration of 10 µg/ml (figure 25).  
 
The overall starting extract, the P. odorata ASE – CH2Cl2 extract, inhibited HL60 cell 
proliferation up to 45 % after 72 hours of incubation with 10 µg extract/ ml medium. To 
recapitulate, fraction F1/2 showed a modification concerning count of cells after 48 h in 
comparison with control, but no significant anti-proliferative effect after 72 hours of 
incubation. But after separating chlorophyll and subsequent fractionation, yielding fractions 
of F1/2, fractions FX/A, C, D, E and F, inhibited HL60 growth up to nearly 100 % (conc.     
10 µg/ml; incubation 72h)  
 
Fraction F1/3 had an effective growth inhibition up to nearly 65 % at a concentration of 10 
µg/ ml. After fractionation of F1/3, the resulting fractions F2/1 to F2/21 were tested. 
F2/11,12,13 and 15 showed an inhibition of growth up to 100%, therefore in the fractions 
F2/11 – 13 and F2/15 non-active compounds were not only eliminated, but the bioactive 
properties become further enriched. 
 
Hence, a considerable enrichment of bioactive properties was attained, as the inhibition of 
growth by the starting ASE - CH2Cl2 extract was only 40 %, whereas fractions F2/11,12,13,15 
and 16 and FX/A, C, D, E, F, respectively, inhibited cell proliferation   by 100 %. 
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4.4.4.4  Separation of chlorophyll of fractions F2/11,12,13,14,15 and 16 
 
Only those fractions sharing highest anti-proliferative activity were selected to separate the 
chlorophyll. Without chlorophyll it is easier to identify each TLC - bar mark, to facilitate the 
separation of different compounds after visualization on TLC plates. Further investigations 
were only performed with fractions after the separation of chlorophyll. 
 
Each fraction was mixed with adequate volume of CH2Cl2 and MeOH:H2O (1:1)    (table 15 
below, methods p21). Then, CH2Cl2 was evaporated at 40°C and 600-800 bar. The 
chlorophyll precipitated in the methanol-water phase and was filtered off. The weight of the 
obtained dried fractions without chlorophyll was measured (table 15 ). 
 
 
 
 
 
 
 
fraction with 
chlorophyll 
CH2Cl2 
(ml) 
MeOH:H2O (1:1) 
(ml) 
yield of fraction 
without chlorophyll 
(in mg) 
yield of fraction 
without chlorophyll 
(in %) 
F2/11  (113.3 mg) 17 17 25.7 23 
F2/12    (90.8 mg) 13.5 13.5 16.3 18 
F2/13  (170.6 mg) 25.5 25.5 41.2 24 
F2/14    (88.6 mg) 13.2 13.2 27.9 32 
F2/15    (26.4 mg)   4   4 2.4 9 
F2/16  (148.5 mg) 22 22 21.6 15 
Table 15  Fractions F2/11-16 including chlorophyll (mg); adequate volume of CH2Cl2 and 
MeOH:H2O for separating procedure; yield (mg) of fraction after separation; yield (%) of 
separated chlorophyll 
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4.4.4.4.1  TLC of fractions F2/11,12,13,14,15,16 
 
 
 
 
 F2/11  F2/12  F2/13  F2/14 F2/15  F2/16 
Figure 26  Above: TLC of fractions F2/11,12,13,14,15,16 
    with chlorophyll (coloured red), solvent system 4; 
    under UV366 without ASR 
 
 
 
 
 
 
    Below: TLC of fractions F2/11,12,13,14,15,16 
    after separation of chlorophyll, solvent system 4; 
    under UV366 without ASR 
 
    Separation was not complete in F2/16, as it still shows red bar marks 
    Concerning the anti-proliferative effect no differences were observed 
    between fractions with or without chlorophyll, therefore the 
    chlorophyll is inactive. 
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4.4.4.4.2 Anti-proliferative activity of fractions F2/11, 12, 13, 14, 15 and 16 after 
separating chlorophyll 
 
To determine the influence of chlorophyll on the anti-proliferative activity, fractions F2/11 – 
16 were also tested after the separation of chlorophyll. HL60 cells were seeded in 24-well 
plates at a concentration of 1 x 10
5
 cells per ml. Then they were incubated for 72 hours with 
10 µg/ml of each fraction (dissolved in DMSO). No differences in effects were observed 
between chlorophyll-containing or chlorophyll-free fractions (figure 27 and 28 below). 
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Figure 27  Anti-proliferative effect of fractions F2/11 to F2/16 without chlorophyll 
HL60 cells were seeded into 24-well plates (1 x 10
5 
 cells/ml), incubated with 10 µg/ml of each fraction for 72 
hours. Control received 0.5 % DMSO which was the highest DMSO concentration, cells had to experience in 
association with highest fraction concentration. Equalization of DMSO was done in all samples to achieve same 
conditions. Cells were counted after 24, 48 and 72 hours of treatment. 
The percentage of proliferation between 24 and 72 hours was determined in comparison to control. Experiments 
were done in triplicate. Asterisks indicate significance compared to untreated control (p<0.05) and error bars 
SEM (see methods, page 20). 
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Figure 28  Anti-proliferative effect of fractions F2/11 to F2/16 including chlorophyll 
HL60 cells were seeded into 24-well plates (1 x 10
5 
 cells/ml), incubated with 10 µg/ml of each fraction for 72 
hours. Control received 0.5 % DMSO which was the highest DMSO concentration, cells had to experience in 
association with highest fraction concentration. Equalization of DMSO was done in all samples to achieve same 
conditions. Cells were counted after 24, 48 and 72 hours of treatment. 
The percentage of proliferation between 24 and 72 hours was determined in comparison to control. Experiments 
were done in triplicate. Asterisks indicate significance compared to untreated control (p<0.05) and error bars 
SEM (see methods, page 20). 
 
 
After separation of chlorophyll fractions F2/11,12,13,15 and 16 showed an effective growth 
inhibition up to 100 % and fraction F2/14 up to 90 % at a concentration of 10µg/ml       
(figure 27). 
 
 
4.4.4.4.3 Obtained fractions F2/11 to F2/16 after separating chlorophyll (in mg) 
 
Based on initial weight of the fractions (including chlorophyll) from which the final fraction 
weight after separation of chlorophyll was subtracted, the calculated difference in weight was 
considered as the amount of chlorophyll. Possibly, also non-chlorophyll constituents were 
separated (figure 29). 
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Fraction F2/11 contained 77 % chlorophyll, F2/12 contained 82 %, F2/13 76 %, F2/14 68 %, 
F2/15 91 % and F2/16 85 %. After separation of the chlorophyll content, which was about 68 
% to 91 % of these fractions , the anti-proliferative activity was fully maintained and found in 
these 6 different fractions (F2/11 – F2/16). 
 
About 23 % of the initial fraction F2/11 contained chlorophyll-free bio-activity, furthermore 
18 % of F2/12, 24 % of F2/13, 32 % of F2/14, 9 % of F2/15 and about  15 % of F2/16. 
 
Relating to fraction F1/2 30.2 % of the initial fraction contained chlorophyll-free bioactitiy. 
After separation of the chlorophyll content, which was about 2/3 of this fraction (F1/2), the 
anti-proliferative activity was fully maintained and found in 5 different fractions (FX/A, FX/C 
– FX/F). 
 
This means that non-active content was eliminated and the active principle became 
increasingly purified. 
 
 
Figure 29  Histogram of fraction weight: chlorophyll included and separated, respectively 
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4.4.5  F3 Column Chromatography (CC) - fractionation of F2/13 
 
41.2 mg were obtained in fraction F2/13 after the separation of chlorophyll, which was the 
highest fraction amount. Therefore, 30 mg of F2/13 was dissolved in 2 ml CHCl3 and used for 
further fractionation by Column Chromatography F3. 
 
The CHCl3 solution was mixed with 430 mg silica gel and evaporated to dryness. It was 
placed on top of a column (98x1 cm), filled with 75 g silica gel. The powdered sample was 
covered with sea sand. The mobile phase, CHCl3:MeOH (95:5; 700 ml), was of higher 
polarity than fraction F2/13, to achieve slower elution and therefore a more precise separation. 
 
Approximately 2 ml fraction, that were obtained after elution, were collected in 318 tubes 
(altogether approximately 700 ml). Ongoing further 300 ml CHCl3:MeOH (95:5) and 300 ml 
CHCl3:MeOH (90:5) were passed through the column by applying vacuum, whereby the last 
two fractions were obtained. 
 
To screen a representative transect of fractions, every tenth was tested by TLC (Mobile phase 
CHCl3:MeOH:H2O: glacial acetic acid 90:10:0.1:0.1). For detection UV366, UV254 and visible 
light were used, before and after spraying the plate with anisaldehyd sulphuric acid reagent 
(ASR). 
 
Fractions with similar looking bar mark pattern were pooled again. The 5 obtained fractions 
F3/1 – 5 were evaporated to dryness and had a total weight of 49.2 mg  (table 16, figure 31). 
The fact, that more material was regained after fractionation (49.2 mg) compared to the input 
(30 mg), is most likely due to a washout of column material. 
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Fractions F3/1 – F3/4 were obtained by the elution of column F3 with the mobile phase 
CHCl3:MeOH (95:5; 700 ml), fraction F3/5 resulted from elution with mobile phase 
CHCl3:MeOH (95:5; 300 ml) and mobile phase CHCl3:MeOH (90:5; 300 ml). 
 
4.4.5.1  Obtained fractions F3/1 - 5 in mg 
 
 
 
 
combined 
fraction 
yield (mg) 
F3/1 3.4 
F3/2 13.0 
F3/3 7.9 
F3/4 3.6 
F3/5 21.3 
           49.2 
Table 16  Fraction F3/1 - F3/5 in mg 
 
F2/13   F3/1   F3/2   F3/3   F3/4                  pooled F3/5 
Figure 30  TLC of fractions F2/13, F3/1 – F3/5 
solvent system CHCl3:MeOH:H2O: glacial acetic acid 
90:10:0.1:0.1; under UV366 with ASR 
Figure 31  Fraction F3/1 to F3/5 in mg 
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4.4.5.2  Anti-proliferative activity of fractions F3/1 to F3/5  
 
To determine the anti-proliferative effect of the fractions F3/1-5 HL60 cells were seeded in 
24-well plates at a concentration of 1 x 10
5
 cells per ml. Then, they were incubated for 72 
hours with 5µg/ml of each fraction. 
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Figure 32  Anti-proliferative effect of fractions F3/1 to F3/5 
HL60 cells were seeded into 24-well plates (1 x 10
5 
 cells/ml), incubated with 5 µg/ml of each fraction for 72 
hours. Control received 0.5 % DMSO which was the highest DMSO concentration, cells had to experience in 
association with highest fraction concentration. Equalization of DMSO was done in all samples to achieve same 
conditions. Cells were counted after 24, 48 and 72 hours of treatment. 
The percentage of proliferation between 24 and 72 hours was determined in comparison to control. Experiments 
were done in triplicate. Asterisks indicate significance compared to untreated control (p<0.05) and error bars 
SEM (see methods, page 20). 
 
 
Fractions F3/3 and F3/4 showed an effective growth inhibiting potential up to nearly 100 % at 
a concentration of 5 µg/ml after 72 hours (figure 32) and therefore, the bio-activity in F3/3 
and F3/4 was approximately 200 % that of F2/13. 
 
Fractions F3/4 and F3/3 were similar in anti-proliferative activity, but the obtained amount of 
F3/3 was higher (7.9 mg vs. 3.6 mg). Consequently the fractionation of F3/3 followed. 
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4.4.6  F4 Reversed Phase-Solid Phase Extraction (SPE) – fractionation of F3/3 
 
For further accumulation of bio-active compounds, fraction F3/3 was fractionated by SPE. 
Firstly, the cartridge (Bond Elut C18; 1210–2058) was conditioned by washing the column 
with 2 RV (2 ml) MeOH and then dried by applying vacuum. After each step of fractionation 
with the different mobile phases the cartridge was dried for 2 min. before the next phase was 
applied. 
 
Fraction F3/3 (7.9 mg) was dissolved in 500µl CHCl3 and placed on top of the cartridge. By 
applying vacuum CHCl3 passed through the column and fraction F4/1 was obtained. 
Additional fractions were collected by eluting the cartridge with 2 RV 90 % MeOH, further 2 
RV 80 % MeOH, 2 RV 70 % MeOH and 4 ml CHCl3:MeOH (1:1), getting fractions F4/2, 
F4/3, F4/4 and F4/5. 
 
4.4.6.1  TLC of fractions F4/1 to F4/5 
 
The obtained fractions were reanalysed by TLC, using the mobile phase 
CHCl3:MeOH:H2O:glacial acetic acid (90:10:0.1:0.1). For detection UV366 was used after 
spraying the plate with ASR (figure 33 below). 
 
 
 
 
 Figure 33  TLC of fractions F4/1 to F4/5; mobile phase CHCl3:MeOH:H2O:glacial acetic acid                 
( 90:10:0.1:0.1); detection under UV366 with ASR 
   F4/1      F4/2     F4/3     F4/4      F4/5 
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TLC showed poor separation of compounds, therefore similarly looking fractions F4/2, F4/3, 
F4/4 and F4/5 were pooled. The weight of obtained dried fractions was measured (F4/1: 5.55 
mg; pooled fraction F4/2-5: 4 mg). A further separation step by Reversed Phase SPE (F5) 
with fraction F4/1 followed.  
 
 
4.4.7 F5 Reversed Phase-Solid Phase Extraction (SPE) – fractionation of F4/1 
 
Firstly the cartridge (Bond Elut C18; 1210–2058) was conditioned by washing the column 
with 2 RV (2 ml) MeOH and then dried by applying vacuum. After each step of fractionation 
with the different mobile phases the cartridge was dried for 2 min. before the next phase was 
applied. 
 
Fraction F4/1 was dissolved in 80µl CHCl3 and placed on top of the cartridge. By applying 
vacuum CHCl3 passed through the column and fraction F5/1 was obtained. 
 
Additional fractions were collected by eluting the cartridge with 2 RV 98 % MeOH, further   
2 RV 96 % and 4 ml CHCl3:MeOH (1:1), getting fractions F5/2, F5/3 and F5/4. 
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4.4.7.1  TLC of fractions F5/1 to F5/4 
 
The obtained fractions were reanalysed by TLC, using the mobile phase 
CHCl3:MeOH:H2O:glacial acetic acid (90:10:0.1:0.1). For detection UV366 was used after 
spraying the plate with ASR (figure 34). 
 
 
 
 
 
 
 
 
 
Prepared TLC showed clear separation of F4/1, therefore F5/1 and F5/2 were pooled as one 
fraction. On the other hand F5/3 and F5/4 were pooled with fractions F4/2,3,4,5 of the F4 
Reversed Phase SPE, because they showed similar bar mark pattern. Finally two fractions, 
named F5/1 and F5/2, were obtained and the anti-proliferative activity was tested (figure 35). 
All in all, there was not a significant further separation of compounds by applying SPE F5.  
F5/1     F5/2       F5/3     F5/4 
Figure 34  TLC of fractions F5/1 to F5/4; mobile phase CHCl3:MeOH:H2O:glacial acetic acid                      
( 90:10:0.1:0.1); detection under UV366 with ASR 
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4.4.7.2   Anti-proliferative activity of fractions F5/1 and F5/2 
 
To determine the anti-proliferative effect of through the last fractionation step obtained 
fractions F5/1 and F5/2 HL60 cells were seeded into 24-well plates at a concentration of 1 x 
10
5
 cells per ml. Cells were incubated for 72 hours with 10 µg/ml per fraction sample. The 
DMSO concentration was adjusted for every sample to 0.5 % (correlated with 10 µg/ml). 
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Figure 35  Anti-proliferative effect of fractions F5/1 and F5/2 
HL60 cells were seeded into 24-well plates (1 x 10
5 
 cells/ml), incubated with 1, 2.5, 5 and 10 µg/ml of fraction 
F5/1 and 10µg/ml of fraction F5/2, respectively, for 72 hours. Control received 0.5 % DMSO which was the 
highest DMSO concentration, cells had to experience in association with highest fraction concentration. 
Equalization of DMSO was done in all samples to achieve same conditions. Cells were counted after 24, 48 and 
72 hours of treatment. 
The percentage of proliferation between 24 and 72 hours was determined in comparison to control. Experiments 
were done in triplicate. All Asterisks indicate significant proliferation inhibition compared to control (p<0.05). 
The red asterisks also mark the significance among the fractions F5/1 and F5/2 (conc. 10µg/ml) and error bars 
SEM (see methods, page 20). 
 
 
The initial fraction F3/3, before applying SPE F4 and SPE F5, showed an effective growth 
inhibiting potential up to nearly 100 % at a concentration of 5 µg/ml after 72 hours (figure 
32). Fraction F5/1 caused a cell growth inhibition around 100 % at a concentration of 10 
µg/ml (figure 35 above) and F5/2 showed 80 % inhibition. 
 
Therefore no further enrichment of bioactive compounds in F5/1 and F5/2 was observed 
through the fractionation of F3/3 by SPE. But fraction F5/1 showed a significant bigger 
antiproliferative effect compared to F5/2. 
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Nevertheless, the advantage of this fractionation step was marginal and therefore the attempts 
to isolate the active principle(s) stopped at this point and mechanistic studies followed. 
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4.4.8  Final testing of potent fractions along the specific workflow 
 
After finishing further fractionation steps Proliferation assays with potent fractions of 
workflow were done to directly compare the anti-proliferative effects at low fraction 
concentrations (3 µg/ml) and to demonstrate the enrichment of bio-activity. 
 
Fractions F2/11, F2/13 and F3/4 showed the highest activities. Since, only fraction F2/11 and 
F2/13 are directly derived from the strong fraction F1/3 and F3/4 is directly derived from 
F2/13, we decided to further analyse fractions F2/11, F2/13 and F3/4. Therefore they were 
subsequently tested in Apoptosis assay and by Western blotting (see p76ff). Fractions FX/A 
to FX/G were eluates of F1/2, which was less potent than F1/3. FX/C and FX/E also showed 
significant activity and were set aside for future projects.  
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Figure 36  Anti-proliferative effect of P. odorata ASE CH2Cl2 extract and fractions FX/A to FX/G, F2/11 to 
F2/16, F3/4, F5/1 and F5/2 
 
HL60 cells were seeded into 24-well plates (1 x 10
5 
 cells/ml), incubated with 3 µg/ml of each fraction for 72 
hours. Control for all fractions received 0.5 % DMSO and control for P. odorata extract received     0.5 % EtOH 
(maximum), respectively, which was the highest concentration, cells had to experience in association with 
highest fraction concentration. Equalization of DMSO and EtOH, respectively, was done in all samples to 
achieve same conditions. Cells were counted after 24, 48 and 72 hours of treatment. 
The percentage of proliferation between 24 and 72 hours was determined in comparison to control. Experiments 
were done in triplicate. Asterisks indicate significance compared to untreated control (p<0.05) and error bars 
SEM (see methods, page 20). 
 74 
To better illustrate and estimate the significant enrichment of potential active compounds 
during continuous fractionation, fractions of the successive workflow were tested by 
Proliferation assays, whereby HL60 cells were seeded into 24-well plates at a concentration of 
1 x 10
5
 cells per ml. Then they were incubated for 72 hours with 5µg/ml and 10µg/ml, 
respectively, of fractions, which are shown in figure 37: 
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Figure 37  Anti-proliferative effect of fractions F1/3, F2/13, F3/3, F3/4, F5/1 and F5/2 
HL60 cells were seeded into 24-well plates (1 x 10
5 
 cells/ml), incubated with 5 and 10 µg/ml, respectively, of 
each fraction for 72 hours. Control for all fractions received 0.5 % DMSO and control for P. odorata ASE 
extract received 0.5 % EtOH (maximum), respectively, which was the highest concentration, cells had to 
experience in association with highest fraction/ extract concentration. Equalization of DMSO and EtOH, 
respectively, was done in all samples to achieve same conditions. Cells were counted after 24, 48 and 72 hours 
of treatment. 
The percentage of proliferation between 24 and 72 hours was determined in comparison to control. Experiments 
were done in triplicate. Asterisks indicate significance compared to untreated control (p<0.05) and error bars 
SEM (see methods, page 20). 
 
 
Fractions F3/4 and F3/3 were similar in anti-proliferative activity at a concentration of            
5 µg/ml, but the obtained amount of F3/3 was higher (7.9 mg vs. 3.6 mg). Consequently, the 
fractionation of F3/3 followed. 
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The obtained fractions F5/1 and F5/2 showed no significant level of activity, so evidently 
there was no further enrichment of active compounds after applying Solid Phase Extractions 
F4 and F5 (see page 68-73). Taken together the results shown in these graphs demonstrate 
that the enrichment of anti-proliferative activity from 10 µg/ml fraction F2/13 and F3/4 was at 
least more than 25 fold. 
 
Fractions F2/11, F2/13 and F3/4 showed most significant anti-proliferative activity at a 
concentration of 3 µg/ml medium after 72 hours of incubation in HL60 cells. Therefore, they 
were subsequently tested by Western blot, analysing components of the cell cycle, because its 
deregulation is a hallmark of cancer and cell cycle protagonists such as Cyclin D1 and 
Cdc25A, oncogenes, which are upregulated in many cancer types (see page 77 ff). 
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                       4.5  ANALYSIS OF CELL CYCLE AND CHECKPOINT REGULATORS 
 
 
Figure 38  Analysis of cell cycle and checkpoint regulators 
 
7
6
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4.5.1  Cell cycle and checkpoint regulators 
 
Each fraction, F2/11, F2/13 and F3/4, showed a significant anti-proliferative effect in HL60 
cells (figure 36, p73), which was 100 % when cells were treated with 3 µg/ml for 72 hours. 
 
Exposure of HL60 cells to 3 µg/ml fraction F2/11 completely blocked Cyclin D1 expression 
after 24 hours, whereas F2/13 reduced the Cyclin D1 level already after 8 hours and its 
consecutive fraction F3/4 down-regulated Cyclin D1 even after 30 minutes. This indicates, 
that F2/11 contains less potent bio-active principles targeting Cyclin D1 expression than 
F2/13. In F3/4, a direct fraction of F2/13, this activity was enriched, which constituted the aim 
of this work. 
 
The proto-oncogene Cyclin D1 is an important regulator of G1 to S phase progression. It 
forms active complexes with its binding partners cyclin dependent kinase 4 and 6 (CDK4 and 
CDK6) that promote cell cycle progression by phosphorylating and inactivating the 
retinoblastoma protein [ALAO, 2007]. The D family of cyclins is associated with various 
proliferative diseases. Temporally, the D cyclins appear in early G1, before the B cyclins, in 
the course of the cell cycle [XIONG et al. 1992a; XIONG et al., 1992b]. 
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Depending on the type of DNA damage (genotoxic stress), ATM or ATR phosphorylates 
Chk2 or Chk1, which in turn phosphorylates Cdc25A. Thereby, Cdc25A becomes inactivated 
and causes the inactivation of Cyclin E-Cdk2.  
 
The intra-S-phase checkpoint link functions to avoid the duplication of damaged or broken 
DNA which would eventually lead to genomic instability. This checkpoint is i.e. regulated by 
ATM/ATR-Chk2-Chk1-Cdc25A. Chk2 was phosphorylated at the activating Thr68 site upon 
treatment with all three fractions tested. 
 
3 µg/ml F2/11 caused a rapid and transient phosphorylation of Chk2 within 2 hours of 
treatment and therefore its activation. In contrast, fraction F2/13 caused phosphorylation of 
Chk2 after 24 hours. Fraction F3/4 caused activation of Chk2 after 8 hours that intensified 
after 24 hours. Chk2 protein levels remained unchanged by incubation of HL60 cells with 
F2/13 and F3/4, but the level decreased upon incubation with F2/11 within 24 hours. 
 
The analysis of Chk2 activity also supported the notion that different active principles are 
considered in F2/11 than in F2/13 and that the bioactive component(s) with higher activity 
becomes enriched in F3/4. Whereas F2/11 induces activation of Chk2 as the earliest of the 
events. 
 
F2/13 and F3/4 induced Chk2 as the latest of the events analysed by Western blotting. This 
indicates that F2/11 contains a genotoxic component, which rapidly causes DNA damage and 
the subsequent gene expression alterations seem to be consequences of this genotoxicity. 
 
In contrast the activation of Chk2 upon treatment with F2/13 and its derivative F3/4 seems to 
be the consequence of DNA damage caused by the comparatively late activation of Caspase 3 
(see figure 41, page 83), which is activated earlier and stronger in F3/4 than in F2/13 and 
perfectly correlates with subsequent Chk2 activation. 
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Cdc25A is a direct target of Chk2 and Chk1 and activation of Chk2 can cause the 
phosphorylation of Ser177 of Cdc25A and Chk1 the phosphorylation of Ser75 of Cdc25A. 
Both phosphorylations inactivate Cdc25A. 
 
F2/11 caused an intense phosphorylation of (Ser177)Cdc25A within 4 hours right after the 
activation of Chk2. Although, (Ser75)Cdc25A became phosphorylated, this was neither due to 
Chk1 nor to p38, because these kinases did not become activated (data not shown). In 
consequence, the phosphorylation level of Cdc2 increased because Cdc25A directly 
dephosphorylates this Cdc2 site, however when inactivated the kinase activity of Wee1 
prevails, which genes rise to accumulating (Tyr15)Cdc2 phosphorylation. 
 
In contrast, F2/13 caused a dephosphorylation of Cdc25A, which was shown to stabilise the 
protein [MADLENER et al., 2009] and also in this case the Cdc25A protein level increased 
due to reduced degradation rate and this was reflected by an increased dephosphorylation of 
(Tyr15)Cdc2 after 8 hours of treatment. Cdc2 (Cdk1) is mandatory for orchestrated G2-M 
transit. Cdc25A and Cdc25C dephosphorylate this protein, which activates its kinase domain. 
Cdc2 protein levels were much more stable in cells treated with F2/13 than with F2/11. This 
is consistent with the higher pro-apoptotic activity of F2/11 compared to F2/13 (page 83ff). 
 
F3/4 caused a very transient phosphorylation of (Ser177)Cdc25A and a weak but more 
sustained phosphorylation of (Ser75)Cdc25A. This inactivation of Cdc25A may have caused 
the slight increase in (Tyr15)Cdc2 phosphorylation and the phosphorylation of 
(Ser75)Cdc25A seemed to be the trigger for its degradation after 24 hours. 
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4.6  INDUCTION OF APOPTOSIS UPON TREATMENT with  
       P. ODORATA EXTRACT and FRACTIONS F2/11, F2/13, 
       F2/14, F2/15 AND F3/4 
 
In the second fractionation cohort, fractions F2/11 and F2/13 were most potent in the 
inhibition of proliferation. Fractions F2/14 and F2/15 were also tested in Apoptosis assay to 
monitor also their activity. 
 
Fractions F3/4 and F3/3 were similar in anti-proliferative activity, but the obtained amount of 
F3/3 was higher (7.9 mg vs. 3.6 mg). Consequently, further fractionation was performed with 
F3/3, which consumed the entire material. Therefore, further investigations regarding 
apoptosis were done with fraction F3/4. 
 
To determine the pro-apoptotic properties of the different fractions HL60 cells were seeded 
into 24-well plates at a concentration of 1 x 10
5
 cells per ml. Cells were incubated for 24 
hours with 3 µg/ml per fraction sample and with 35 µg/ml of P. odorata ASE - CH2Cl2 
extract to demonstrate the enrichment of pro-apoptotic activities throughout the higher orders 
of fractionations. After incubation percentages of apoptotic cells were calculated. 
 
Fraction F2/11 and F3/4 were the most active ones after 24 hours, because they induced 
apoptotic cell death in 100 % of HL60 cells. The higher concentrated P. odorata extract 
(35µg/ml) was sufficient to eliminate around 65 % of HL60 cells, but the P. odorata extract at 
a low concentration of 3 µg/ml was inactive (figure 39). 
 
The most potent apoptotic fractions after 24 hours of incubation, F2/11 und F3/4, were further 
diluted (cells were incubated with 0.4 µg/ml, 0.8 µg/ml and 1.5µg/ml of fractions). F2/11 
caused 60 % cell death at a concentration of 1.5µg/ml medium, but fraction F3/4 caused 
100% at the same concentration and even 60 % when applying the concentration of 0.8 µg/ml 
medium and this result induced that the pro-apoptotic properties were enriched at least by 45 
fold in fraction F3/4 (figure 39 and 40). 
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Figure 39  Induction of apoptosis by the P. odorata ASE - CH2Cl2 extract and 
proliferative active fractions F2/11, F2/13, F2/14, F2/15 and F3/4  
HL60 cells were seeded into 24-well plates and incubated with P. odorata CH2Cl2 
extract (conc. 35µg/ml and 3 µg/ml) and with fractions F2/11, F2/13, F2/14, F2/15 
and F3/4 (conc. 3 µg/ml for 24 hours). Controls and all fractions received 0.5 % 
DMSO and control for P. odorata ASE extract received 0.5 % EtOH, respectively, 
which was the highest concentration, cells had to experience in association with 
highest fraction/extract concentration. Then, cells were double stained with 
Hoechst 33258 and propidium iodide and examined under the microscope with UV 
light connected to a DAPI filter. Nuclei with morphological changes which 
indicated apoptosis or necrosis were counted and percentages of vital, apoptotic 
and necrotic cells were calculated. Experiments were done in triplicate. Asterisks 
indicate significance compared to untreated control (p<0.05) and error bars SEM 
(see methods, page 20). 
Figure 40  Induction of apoptosis by the active fractions F2/11 and F3/4 
HL60 cells were seeded into 24-well plates and incubated with fractions 
F2/11 and F3/4 (conc. 1.5 µg/ml, 0.8 µg/ml, 0.4 µg/ml) for 24 hours. 
Control received 0.5 % DMSO, which was the highest concentration, 
cells had to experience in association with highest fraction 
concentration. Equalization of DMSO was done in all samples to 
achieve same conditions. Then, cells were double stained with Hoechst 
33258 and propidium iodide and examined under the microscope with 
UV light connected to a DAPI filter. Nuclei with morphological changes 
which indicated apoptosis or necrosis were counted and percentages of 
vital, apoptotic and necrotic cells were calculated. Experiments were 
done in triplicate. Asterisks indicate significance compared to untreated 
control (p<0.05) and error bars SEM (see methods, page 20). 
8
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4.7 COMPARISON of the ANTI-PROLIFERATIVE ACTIVITY with       
the PRO-APOPTOTIC ACTIVITY of FRACTIONS F2/11, F2/13       
and F3/4 
 
 
 
 
fraction 
 
anti-proliferative activity 
[conc. 3µg/ml] 
 
 
pro-apoptotic activity 
[conc. 3µg/ml] 
after 8 hours 
 
 
pro-apoptotic activity 
[conc. 3µg/ml] 
after 24 hours 
 
F2/13 
 
 
100 % 
 
5 % 
 
40 % 
F2/11 
 
98 % 20 % 100 % 
F3/4 
 
100 % 40 % 100 % 
 
 
 
 
Proliferation assays with potent fractions of workflow were done and fractions F2/11, F2/13 
and F3/4 showed the highest anti-proliferative activitiy at low fraction concentrations            
(3 µg/ml). Fraction F3/4 was the most pro-apoptotic active ones after 8 hours of incubation. 
Fraction F2/11 and F3/4 were the most active ones after 24 hours, because they induced 
apoptotic cell death in 100 % of HL60 cells. 
 
Fractions F2/13, F2/11 and F3/4 were further tested regarding cell death induction in HL60 
cells because a major property of cytotoxic anticancer drugs is the potential to elicit apoptosis. 
 
Table 17  Comparison of F2/11, F2/13 and F3/4 in anti-proliferative with pro-apoptotic activity 
 
  
4.8  ANALYSIS OF APOPTOSIS RELATED PROTEINS 
 
 
 
8
3
 
Figure 41  Analysis of apoptosis related proteins 
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We analysed apoptosis with a highly sensitive method that identifies very early hallmark 
phenotypes long before metabolism ceases and the cell actually dies, sometimes days later 
[FRITZER-SZEKERES et al., 2000; ROSENBERGER et al., 2000; GRUSCH et al., 2001]. 
Fraction F2/11 showed at a concentration of 1.5µg/ml  60 % apoptosis after 24 hours. 
Fraction F3/4 caused 65 % apoptotic cells at a concentration of 0.8 µg/ml after 24 hours. At a 
concentration of 3 µg/ml and after 24 hours a distinctive cleavage of Caspase 3 to 19 kDa and 
12 kDa was shown, which is indicative for its activation. 
 
Western blotting aimed to elucidate different pro-apoptotic mechanism in the fractions F2/11, 
F2/13 and F3/4. Low concentrations of all fractions (3 µg/ml) were shown to induce H2AX 
phosphorylation (γH2AX) in HL60 cells indicating genotoxicity. F2/11 caused 
phosphorylation of H2AX within 30 min, F2/13 within 24 hours and F3/4 after 8 hours. This 
is in agreement with the presence of a DNA damaging compound in F2/11, whereas induction 
of γH2AX is the consequence of the activation of caspases by F2/13 and F3/4 as evidenced by 
PARP cleavage, in which this property was enriched. In F3/4 an additional execution caspase 
might have become activator to achieve this efficient signature type cleavage of PARP. 
 
Caspases are the most important enzymes for apoptosis. Initiator caspases, like  Caspase-8 
and Caspase-9, cleave downstream pro-form caspases (Caspase 3/7/6). Caspase-3 plays a key 
role during apoptosis. It is totally or partially responsible for the proteolytic cleavage of many 
key proteins such as the nuclear enzyme poly (ADP-ribose) polymerase (PARP). Also 
Caspase 6 and 7 cleave PARP and cooperate in this aspect [FERNANDES-ALNEMRI et al., 
1994]. 
 
Poly (ADP-ribose) polymerase (PARP) is a nuclear enzyme that is activated by DNA strand 
breaks to participate in DNA repair [PIEPER et al., 1999]. Activated Caspase 3 cleaves the 
116 kDA death substrate PARP into an 85 kDa fragment.  
 
All fractions induced acetylation of -tubulin. This implicates that they stabilize microtubule 
[PIPERNO et al., 1987], reminiscent of the mechanism of taxol and therefore, trigger mitotic 
arrest and apoptosis, which was in fact observed at a concentration of 3 µg/ml after 8 hours in 
F2/11 (20%) and F3/4 (40%), whereas this concentration of F2/13 had an apoptotic effect of 
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40 % after 24 hours. Tilting the fine-tuned equilibrium of polymerized/de-polymerized 
microtubule is incompatible with normal cell division and this causes not only cell cycle 
arrest, but also apoptosis. 
 
Also, here F2/11 differed from F2/13 and F3/4, because in F2/11 tubulin acetylation was rapid 
and strong, whereas in fraction F2/13 it was observed after 24 hours only and less pronounced 
than in F2/11. F3/4 showed an enrichment in the tubulin acetylation property. 
 
Therefore we could separate two very distinct anti-neoplastic properties in the fraction of the 
P. odorata ASE – CH2Cl2 extract. A genotoxic property which also causes strong tubulin 
polymerization inhibits cell growth and induces apoptosis in F2/11, and an even stronger pro-
apoptotic property, which ist not genotoxic but have a stronger impact on the expression of 
the oncogenes Cyclin D1 and Cdc25A as well as an activation of caspases. 
 
This study evidences, that a traditional healing plant for the treatment of severe and chronical 
inflammations has the potential to be developed for an anti-neoplastic remedy. The discovery 
and the successful separation of a genotoxic property from an even more potent anticancer 
property that targets the expression of two potent oncogenes, Cyclin D1 and Cdc25A, makes 
further approaches to identify this highly pro-apoptotic component, a reasonable and fruitful 
undertaking. 
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5  CONCLUSION 
 
Our investigations took aim at the anti-proliferative and pro-apoptotic active dichloromethane 
extract of the ethnopharmacological Mayan healing plant, Pluchea odorata (Asteracea) 
[GRIDLING et al., 2009]. To separate the principles from the aerial parts of P. odorata with 
anti-neoplastic activity bioassay-guided fractionation was carried out by (VLC) vacuum liquid 
chromatography (PE,CHCl3-MeOH,MeOH-H2O in different ratios), normal (CC) column 
chromatography (chloroform-methanol-water gradient) on silica gel KG60 and RP-18 (SPE) 
solid phase extraction (CHCl3,MeOH,H2O in different ratios). The bioassay-guided 
fractionation indicated that the anti-proliferative activity of P. odorata was due to fractions 
containing highly apolar constituents. 
 
The most potent fractions that were separated throughout the workflow were tested by 
proliferation assay in HL60 cells to directly compare the anti-proliferative effects at low 
fraction concentration (3µg/ml) and to demonstrate the enrichment of bio-activity. The 
obtained results demonstrate that the enrichment of anti-proliferative activity was at least 
more than 25 fold. 
 
Fractions F2/11, F2/13 and F3/4 showed most significant anti-proliferative activity at a 
concentration of 3 µg/ml medium after 72 hours of incubation in HL60 cells. Therefore they 
were subsequently tested by apoptosis assay and western blot, analysing components of the 
cell cycle and eliciting its deregulation, which is a hallmark of cancer. 
 
Fractions showed the ability to down-regulate cell cycle protagonists such as Cyclin D1 and 
Cdc25A. These are oncogenes, which are upregulated in many cancer types. The Cyclin D1 
expression differed in all three fractions, this indicates that the bio-active principles are 
different in each fraction. F2/13 contained more potent Cyclin D1 inhibitory activity than 
F2/11, which was further enriched in fraction F3/4. 
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F2/11 induces activation of Chk2 as the earliest of the events, whereas F2/13 and F3/4 as the 
latest. Chk2 protein levels decreased upon incubation with F2/11, but remained unchanged by 
incubation of HL60 cells with F2/13 and F3/4. This data attests the presence of different 
active principles contained in F2/11 and F2/13 and the enrichment of bioactive components in 
F3/4. 
 
Fraction F2/11 obviously contains a genotoxic component which rapidly causes DNA damage 
and the subsequent gene expression alterations seem to be consequences of this genotoxicity. 
On the other side, the DNA damage upon treatment with F2/13 and its derivative F3/4 caused 
by the comparatively late activation of Caspase 3, which is activated earlier and stronger in 
F3/4 than in F2/13, elicits the activation of Chk2. (Ser177)Cdc25A is phosphorylated 
intensive by F2/11, in contrast, F2/13 caused a dephosphorylation of Cdc25A, which was 
shown to stabilise the protein. 
 
Fraction F2/11 and F3/4 were the most active ones after 24 hours, because they induced 
apoptotic cell death in 100 % of HL60 cells after 24 hours, therefore they showed the higher 
pro-apoptotic activity compared to F2/13. The pro-apoptotic properties were enriched at least 
by 45 fold in fraction F3/4. All three fractions induced acetylation of α-tubulin and therefore, 
they trigger mitotic arrest and apoptosis. Two very distinct anti-neoplastic properties in the 
fraction of the P. odorata ASE – CH2Cl2 extract were separated, a genotoxic and and even 
stronger pro-apoptotic property. 
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6  ABSTRACT 
 
The aim of this diploma theses was to enrich the anti-neoplastic activities of Pluchea odorata 
(L.) Cass., Asteraceae, and analyse the underlying mechanisms. In recent investigations a 
strong anti-neoplastic activity was found from aerial parts of Pluchea odorata, a plant used by 
the Maya to treat severe inflammatory conditions [GRIDLING et al., 2008]. 
 
Hence, bioassay-guided fractionation was carried out to enrich the active compound(s). 
Initially the plant material was extracted by (ASE) accelerated solvent extraction obtaining 
the bioactive P. odorata ASE - CH2Cl2 extract. It was re-chromatographed by (VLC) vacuum 
liquid chromatography (PE,CHCl3-MeOH,MeOH-H2O in different ratios), normal (CC) 
column chromatography (chloroform-methanol-water gradient) on silica gel KG60 and RP-18 
(SPE) solid phase extraction (CHCl3,MeOH,H2O in different ratios). The bioassay-guided 
fractionation indicated that the anti-proliferative activity of P. odorata is due to a fraction 
containing highly apolar constituents. 
 
As a result of five fractionation steps, an at least 25 fold enrichment of anti-proliferative 
activity was reached. To test the efficiency in anticancer effects the inhibition of proliferation 
and the induction of cell death were investigated in HL60 cells and MCF7 cells. The most 
potent fractions F2/11, F2/13 and F3/4 were tested by western blot to obtain evidence of 
underlying mechanisms. Differences between fractions in Cyclin D1 expression indicate, that 
F2/11 contains less potent principles than F2/13, but in F3/4 the activity was enriched. 
 
Chk2 was phosphorylated at the activating Thr68 site upon treatment with all three fractions 
tested. F2/11 induced activation of Chk2 as the earliest of the events. Chk2 activity supported 
the notion that different active principles were contained in F2/11 and in F2/13, and that those 
components that more specifically interfered with cell cycle progression, became enriched in 
F3/4. Fraction F2/11 and F3/4 were the most pro-apoptotic active ones and the pro-apoptotic 
properties were enriched at least by 45 fold in fraction F3/4. Genotoxicity of fraction F2/11 
was indicated by rapidly inducing phosphorylation of H2AX. Apparently, there is a DNA 
damaging compound in F2/11, whereas induction of γH2AX is the consequence of the 
activation of caspases by F2/13 and F3/4 as evidenced by PARP cleavage, in which this 
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property was enriched. The acetylation of -tubulin implicated that all three fractions 
stabilized microtubule, reminiscent of the mechanism of taxol and therefore, trigger mitotic 
arrest and apoptosis. F3/4 showed an enrichment in the tubulin acetylation property. Thus, we 
could separate two very distinct anti-neoplastic properties in the fraction of the P. odorata 
ASE – CH2Cl2 extract. 
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7  ZUSAMMENFASSUNG 
 
Ziel dieser Diplomarbeit war die Anreicherung der anti-neoplastischen Aktivität der 
guatemalischen Pflanze Pluchea odorata (L.) Cass., Asteraceae, und die Untersuchung der 
zugrunde liegenden Mechanismen dieser Aktivität. Neueste Untersuchungsergebnisse zeigen 
die starke anti-neoplastische Aktivität der oberirdischen Pflanzenteile dieser traditionellen 
Heilpflanze, welche bei den Maya zur Behandlung schwerer Entzündungen eingesetzt wird 
[GRIDLING et al., 2008]. 
 
Auf Basis dieser Ergebnisse wurden zur Anreicherung aktiver Verbindungen, Bio-Assay 
unterstützte Fraktionierungen durchgeführt. Zu Beginn wurde das getrocknete, pulverisierte 
Pflanzenmaterial mit Hilfe der ASE (accelerated solvent extraction) extrahiert um das 
bioaktive P. odorata ASE - CH2Cl2 Extrakt zu erhalten. Darauf folgten die 
Fraktionierungsschritte durch (VLC) Vacuum liquid chromatography (PE,CHCl3-
MeOH,MeOH-H2O in unterschiedlichem Mischungsverhältnis), durch   (CC) Normal column 
chromatography (Chloroform-Methanol-Wasser Gradient) auf Silikagel KG60 und durch RP-
18 (SPE) Solid phase extraction (CHCl3,MeOH,H2O in unterschiedlichem 
Mischungsverhältnis). Demzufolge ist die anti-proliferative Aktivität der P. odorata auf eine 
Fraktion zurückzuführen, welche hoch polare Bestandteile aufweist. 
 
Durch fünf aufeinander folgende Fraktionierungsschritte konnte eine 25-fache Anreicherung 
der anti-proliferativen Aktivität erreicht werden. Zur laufenden Überprüfung der anti-
kanzerogenen Wirkung der erhaltenen Fraktionen wurde die Proliferationshemmung und die 
Induktion des Zelltodes in HL60 Zellen und MCF7 Zellen getestet. Die wirksamsten 
Fraktionen waren F2/11, F2/13 und F3/4, welche in der Folge mittels Western blot getestet 
wurden um zugrunde liegende Mechanismen aufzuzeigen. Die jeweils unterschiedliche 
Cyclin D1 Expression der einzelnen Fraktionen hat gezeigt, dass die Fraktion F2/11 
schwächer wirksame Komponenten enthält als F2/13, und weist zugleich auf eine 
Aktivitätsanreicherung in Fraktion F3/4 hin. 
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Die Inkubation der Zellen mit den Fraktionen F2/11, F2/13 und F3/4 löste eine 
Phosphorylierung von Chk2 am aktivierenden Thr68 aus, wobei  Fraktion F2/11 die Chk2 
Aktivierung zum frühesten Zeitpunkt auslöste. Die beobachtete Chk2 Aktivität untermauerte 
den Hinweis darauf, dass sich die aktiven Verbindungen in F2/11 und F2/13 unterschieden. 
Gleichzeitig zeigte sie deutlich, dass diese Verbindungen, welche vornehmlich in die 
Zellzyklus-Progression eingegriffen haben, in F3/4 angereichert wurden. 
 
Fraktion F2/11 und F3/4 wiesen die am stärksten pro-apoptotisch aktiven Verbindungen auf, 
wobei es durch die Fraktionierungsschritte zu einer 45-fachen Anreicherung in Fraktion F3/4 
kam. Den Beweis der Genotoxizität der Fraktion F2/11 lieferte die rasch ausgelöste 
Phosphorylierung von H2AX. Offensichtlich ist in Fraktion F2/11 eine DNA-schädigende 
Komponente enthalten. Dahingegen fand die Induktion von γH2AX durch F2/13 und F3/4 in 
Folge der Aktivierung von Caspasen statt, was durch die Aufspaltung von PARP belegt 
wurde. 
 
Die Acetylierung des -Tubulin hat gezeigt, dass die Mikrotubuli durch alle 3 Fraktionen 
stabilisiert wurden, und in der Folge mitotischen Arrest und Apoptose auslöste, was an den 
Mechanismus des Taxol erinnert. Fraktion F3/4 zeigte eine Steigerung der Tubulin-
acetylierenden Wirkung. Somit haben wir die Auftrennung und Isolierung von zwei 
verschiedenen anti-neoplastisch wirksamen Komponenten oder Verbindungsgemischen aus 
dem P. odorata ASE – CH2Cl2 Extrakt erreicht. 
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